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Abstract 
The low density lipoprotein receptor (LDLr) is a 160 kDa membrane protein important in 
the maintenance of cholesterol levels in plasma and a member of the LDLr family of 
endocytic proteins. Mutated receptors contribute to high cholesterol levels in familial 
hypercholesterolemia (FH). A 140-kDa soluble form of the LDLr was detected in the 
medium of cultured mammalian cells and established to be a product of ectodomain 
shedding. Sheddase-mediated ectodomain release of the LDLr was stimulated by phorbol 
esters, a protein kinase C (PKC) activator, and sensitive to inhibition by metalloprotease 
inhibitors. Furthermore, the shedding of two internalisation defective receptors, namely 
792-LDLr and JD-LDLr has been investigated and found to be shed more efficiently than 
the wt-LDLr. The tumour necrosis factor-α converting enzyme (TACE) a TNF-α 
sheddase, and a member of a disintergrin and metalloprotease (ADAM) family, was 
suggested to be involved in the shedding of LDLr. To investigate the role of TACE in 
LDLr shedding, TACE-deficient cell lines expressing wild-type or mutant LDLr were 
analysed for the ectodomain release. Constitutive levels of LDLr shedding occurred in 
the absence of TACE activity in mouse fibroblasts. On the other hand, stimulated 
shedding of wt-LDLr and 792-LDLr was dependent on TACE because when TACE is 
absent, no increase in shedding was observed, while the JD-LDLr could be shed by 
another sheddase since phorbol stimulation of the JD-LDLr release occurred in mouse 
fibroblasts deficient in TACE. In Chinese hamster ovary (CHO) cells, both the 
constitutive and phorbol-stimulated shedding of all the LDLr constructs were dependent 
on TACE activity. Soluble LDLr levels, sheddase activity and ADAM 10 expression 
were higher in the TACE-/- mouse fibroblasts than in the CHO TACE deficient cell line, 
thus ADAM 10 might play a role in the constitutive LDLr shedding in mouse fibroblasts. 
The in vivo formation of soluble LDLr was also explored. A soluble form of the LDLr of 
~120 kDa was identified in human plasma by Western blot analysis. To determine the 
functional integrity of soluble LDLr, the binding of plasma LDL to a recombinant 
soluble LDLr was investigated. Recombinant soluble LDLr was shown to bind plasma 
LDL. The presence of soluble LDLr in plasma suggests that the ectodomain shedding of 
membrane-bound LDLr might play a role in LDL metabolism.  




1. Introduction  
Cholesterol maintenance is essential for cellular functions, in the synthesis of hormones, 
and for the structural integrity of plasma membranes of cells (Goldstein et al., 1985; 
Simons and Ikonen, 2000; Brown and Goldstein, 1986). Cholesterol, a hydrophobic 
molecule, is transported in an esterified form in the blood within a low density 
lipoprotein (LDL) particle (Brown and Goldstein, 1986). The LDL particle is made up of 
a large number of phospholipids and a single copy of apolipoprotein B-100 (apo B-100), 
surrounding the cholesterol molecule. LDL is a large particle with a molecular weight 
ranging from 2500 kilo Daltons (kDa) to 3500 kDa (Fisher et al., 1975). LDL binds to 
the LDL receptor (LDLr), which was identified as the receptor involved in cholesterol 
homeostasis by Goldstein and Brown, the pioneers in the field (Brown and Goldstein, 
1986).  The LDLr binds apo B-100 containing LDLs and apo E-containing lipoproteins 
[very LDLs (vLDLs) and chylomicrons]. The liver is the main site where plasma levels 
of cholesterol concentrations are controlled. The LDLr will be discussed further in terms 
of its structure, function, regulation and ectodomain release.  
  2 
1.1 The LDLr 
1.1.1 LDLr gene structure 
The LDLr gene containing 18 exons and 17 introns, is located on chromosome 19 
(Lehrman et al., 1987). The LDLr is a mosaic protein as different exons transcribe 
different domains. The extracellular domain is transcribed by exons 2 to 16. The 
transmembrane and cytoplasmic domains are transcribed by exons 16-18 (Yamamoto et 
al., 1984; Sudhof et al., 1985). The LDLr promoter contains a sterol regulatory element, 
which is sensitive to changes in cholesterol levels. The messenger ribonucleic acid 
(mRNA) is 5.3 kb in length (Yamamoto et al., 1984) and has a 2.5 kb untranslated 
region, which may serve to provide stability to the mRNA transcripts (Kong et al., 2006).  
 
1.1.2 LDLr protein structure 
The LDLr is a 160 kDa,  type-I membrane protein and is 839 amino acid residues in 
length after the post-translational removal of the 21 amino acid signal sequence 
(Schneider et al., 1982; Yamamoto et al., 1984). The tertiary structure of the LDLr is 
divided into 5 domains. Starting from the N-terminus the first domain is a ligand binding 
domain, followed by an Epidermal Growth Factor (EGF) precursor homology domain, an 
O-glycosylated domain, a hydrophobic membrane-spanning domain, and a C-terminal 
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The ligand binding domain is comprised of 7 repeats, also called LDL receptor type A 
(LA) modules (Jeon and Blacklow, 2005). Each repeat is 40 amino acids long, and 
contains six cysteine residues. Each of the cysteine residues are disulphide bonded to 
another cysteine within the repeat in the following pattern: Cys I to Cys III, Cys II to Cys 
V, Cys IV to Cys VI (Bieri et al., 1998). The EGF precursor homology domain consists 
of two EGF cysteine-rich repeats (named EGF repeat A and B), followed by six YWTD 
repeats within a YWTD motif, and another cysteine-rich EGF repeat (EGF repeat C). 
Deletions of the EGF domain suggest that this region is important for binding to LDL, 
but not for Apo E. It is important however for the release of Apo E in the endosome and 
Figure 1.1: The domain structure of the LDLr (adapted from 
Yamamoto et al., 1984 and Innerarity, 2002). 
The LDLr is divided into ligand binding domain (322 amino acids), followed by 
an EGF precursor homology domain (~350 amino acids), an O-glycosylated 
domain (48 amino acids), a hydrophobic membrane-spanning domain (22 amino 
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recycling of the receptor (Davis et al., 1987). The YWTD motif forms a “6-bladed β-
propeller domain” that is responsible for the release of the ligand in the endosome (Herz, 
2001). Deletion mutants showed that Apo E and Apo B binding is not dependent on LA 
repeats 1 and 2 and EGF repeat B, while LA repeats 3-7 and EGF repeat A are important 
for Apo B binding. The only LA repeat important in the binding of apo E to the LDLr is 
LA repeat 5 (Russell et al., 1989; Hussain et al., 1999). The crystal structure showed that 
the β-propeller domain displaces the ligand at low pH and binds to repeats 4 and 5 
(Innerarity, 2002). The O-glycosylated domain is rich in serine and threonine residues 
that are O-glycosylated and this domain is not essential for the functioning of the 
receptor (Davis et al., 1986; Hussain et al., 1999). The transmembrane domain is 
composed of hydrophobic residues. The C-terminal cytoplasmic tail of the LDLr is 40 
amino acids long and has a NXPY internalisation sequence (where X is any amino acid) 
which is important for endocytosis (Yamamoto et al., 1984; Chen et al., 1990; Herz, 
2001). The full-length, membrane bound form of the LDLr is also released as a soluble 
fragment, which will be discussed later in section 1.2.1.4. 
 
1.1.3 Function of the LDLr 
The primary function of the LDLr is to maintain plasma and cellular cholesterol levels by 
a process known as endocytosis (Goldstein et al., 1985; Brown and Goldstein, 1986). 
Approximately 70% of plasma LDL is cleared by hepatic LDLr through this process. 
Loss or inadequate function of the LDLr gives rise to inadequate LDL clearance and 
accumulation of LDL in the circulation resulting in a condition known as familial 
hypercholesterolemia (FH). Untreated FH can lead to the deposition of LDL in arteries 
with the concomitant formation of atherosclerotic plaques, a life-threatening condition 
called atherosclerosis (Brown and Goldstein, 1986; Glass and Witztum, 2001). 
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The LDLr is synthesised in the endoplasmic reticulum (ER) and mature LDLr is 
expressed at the cell surface, where circulating LDL binds to the receptor (Fig. 1.2) 
(Yamamoto et al., 1984; Brown and Goldstein, 1986; Gent and Braakman, 2004). The 
LDL-LDLr complex becomes internalised through clathrin coated pits which form 
vesicles by budding off from the membrane, and giving rise to the endosome. Once the 
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Figure 1.2: LDLr-mediated endocytosis (adapted from Brown and Goldstein 
1986, and Gent and Braakman, 2004). 
(1). Synthesis of the LDLr in response to low cellular cholesterol levels (2). LDLr is 
glycosylated and directed to the membrane (3). LDL binds to the receptor (4). The LDL is 
endocytosed via budding off the membrane to form a vesicle, called an endosome. A drop in 
pH allows for ligand release (5). LDLr is recycled to the membrane (6). The Apo B-100 
portion is degraded to amino acids (7) in the lysosome (8). Increases in cholesterol 
concentrations inhibit the synthesis of cholesterol as well as the synthesis of the LDLr.  
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receptor complex. The LDL particle is broken down to release cholesterol to be used in 
downstream events. The protein component of LDL, apo B-100 is degraded while the 
LDLr is recycled to the membrane. The process is controlled through a feedback 
mechanism which prevents overloading of cholesterol and thus maintains cellular 
cholesterol levels. This process is inhibited by increasing cholesterol concentrations 
(Yamamoto et al., 1984; Innerarity, 2002). 
 
1.1.4 LDLr family 
The LDLr family consists of the LDLr, the vLDL receptor (vLDLr), the LDLr related 
protein-1 (LRP)-1 a, LRP-1 b, megalin (gp330/LRP-2) (Kounnas et al., 1993), LRP-5, 
LRP-6, and apolipoprotein E receptor 2 (ApoER2/LRP-8) (Hussain et al., 1999; Nykjaer 
and Willnow, 2002; Jeon and Blacklow, 2005). Members of this family all share the 
same basic domain structure: a ligand binding domain, an EGF precursor homology 
domain, a hydrophobic membrane-spanning domain and a C-terminal cytoplasmic tail. In 
addition, some of the members have an O-glycosylated domain (Fig. 1.3). The receptors 
differ in the number of repeats within the ligand binding domain, the number of EGF 
repeats and the number of YWTD repeats (Hussain et al., 1999; Nykjaer and Willnow, 
2002) The structure of LRP-1 is slightly different compared to the rest, as it is made up 
of an α- and a β-subunit which are covalently linked. A common feature amongst the 
LDLr family members is that they are expressed at the cell surface and undergo receptor-
mediated endocytosis to transport ligands into cells. Another feature is that members of 
the LDLr family bind a number of unrelated ligands, in addition to their specific ligand, 
all of which are calcium dependent. All of the receptors are able to bind receptor 
associated protein (RAP), although to different levels. LDLr family members are 
expressed fairly widely throughout the different tissues (Hussain et al., 















Ligand binding domain 






Figure 1.3: Core members of LDLr family (adapted from Gent and Braakman, 
2004 and Jeon and Blacklow, 2005).
The domain structures of the LDLr family members. The LDLr, vLDLr and apoER2 share 
similar overall domain structures. The LRP-1 and megalin are the largest members and are 
comprised of more ligand binding domains. LRP-5 and LRP-6 share a similar structure. 
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1.1.5 LDLr regulation 
The transcriptional regulation of the LDLr gene is controlled by intracellular cholesterol 
levels which further affect a group of proteins to activate or down-regulate the LDLr 
gene. In addition, the LDLr is also regulated at the post-translational level. 
 
1.1.5.1 Sterol-regulatory element-binding proteins (SREBPs) 
The LDLr is regulated at the transcriptional level by SREBPs which are important in 
cholesterol homeostasis and are controlled by a feedback regulation due to the 
accumulation of end products. SREBPs control transcriptional levels of the LDLr gene, 
to increase or decrease uptake of cholesterol into the cell. SREBPs also regulate genes 
involved in the synthesis of cholesterol (Sakai and Rawson, 2001).  
 
The family of SREBPs are made up of SREBP-1a, SREBP 1-c  and SREBP-2 
(Yokoyama et al., 1993; Simons and Ikonen, 2000; Sakai and Rawson, 2001; Kong et al., 
2006; Martini and Pallottini, 2007). SREBPs are membrane proteins and SREBP-2 is the 
main protein that is important in the regulation of cholesterol maintenance (Martini and 
Pallottini, 2007). SREBPs are regulated by proteolytic cleavage to produce active 
proteins in the ER and in the presence of cholesterol remain as inactive proteins attached 
to retention proteins (either Insig 1 or 2) and the chaperone protein, SREBP cleavage 
activating protein (SCAP). SCAP has a sterol sensory domain, so when cellular 
cholesterol concentrations are low the SCAP/SREBP complex is transported to the Golgi 
where it is cleaved consecutively by a Site-1 and Site-2 protease, releasing the N-
terminal regions of SREBP which translocates to the nucleus. Binding of SREBPs to the 
sterol regulatory response elements within gene promoters, allows for the increase in 
transcription of genes that increase the levels of cholesterol synthesis such as 3-hydroxy-
  9 
3-methylglutaryl Co-enzyme A (HMG CoA) synthase and HMG CoA reductase, as well 
as the genes involved in cholesterol uptake such as the LDLr (Simons and Ikonen, 2000; 
Sakai and Rawson, 2001; Martini and Pallottini, 2007). 
 
HMG CoA reductase is the rate-limiting enzyme in the production of cholesterol (Brown 
and Goldstein, 1986). Statins are inhibitors of HMG CoA reductase, which inhibits the 
production of cholesterol synthesis and increasing the cleavage of SREPB-2 with the 
concomitant increase in the production of LDLr mRNA and LDLr protein levels. Statins 
are used in the treatment of FH. 
 
Estrogen, growth factors, cytokines, insulin and phorbol esters like phorbol myristate 
acetate (PMA), affect LDLr transcription by either increasing the binding of transcription 
factors to the LDLr promoter, or activating SREBPs or the activation of  extracellular 
signal-regulated kinase (ERK) signaling cascades, all of which increase LDLr 
transcription (Mehta et al., 2002; Smith et al., 2004; Kong et al., 2006).  
 
1.1.5.2 Post-translational regulation of the LDLr by proprotein convertase subtilisin 
kexin 9 (PCSK9) 
A newly identified player in the post-translational regulation of the LDLr is the PCSK9, 
previously known as neural apoptosis regulated convertase 1 (NARC-1), a member of the 
serine protease convertase family transcribed by the NARC-1 gene (Benjannet et al., 
2004). Mutations in this gene were discovered when some patients displayed high LDL 
levels, but had no associated mutations in either the receptor or in the ligand protein apo 
B-100, the two genes that are associated with FH (Haddad et al., 1999). PCSK9 was 
identified as the third gene which plays a role in FH (Timms et al., 2004; Dubuc et al., 
  10 
2004). Early studies indicated that PCSK9 does indeed have a role in cholesterol 
maintenance when this gene was identified to be regulated by sterols and further 
evidence showed that it was regulated by SREBP-2 and upregulated by statins (Dubuc et 
al., 2004).  
 
PCSK9 is secreted from the cell and secretion requires autocatalysis, a mechanism which 
cleaves the prodomain from the catalytic domain, but the prodomain stays attached to the 
catalytic domain as a complex (Li et al., 2007a; McNutt et al., 2007, Kwon et al., 2008). 
 
PCSK9 reduced LDLr expression in cultured lymphocytes and in rat hepatoma cells 
(Benjannet et al., 2004), while mice that had adenovirus-mediated expression of PCSK9 
were observed to have increased plasma levels of LDL due to reduced hepatic LDLr 
(Maxwell and Breslow, 2004). PCSK9 had no effect on mRNA levels, while lowering 
surface LDLr expression in cultured human cells as well as transfected cells (Maxwell et 
al., 2005).  
 
Studies on the overexpression of PCSK9 indicated that PCSK9 reduced mature LDLr 
protein quantities without affecting the synthesis of LDLr and was dependent on 
catalytically active PCSK9 (Park et al., 2004; Maxwell et al., 2005; Benjannet et al., 
2006; Homer et al., 2008). PCSK9-mediated degradation of the LDLr was suggested to 
occur independently of the adaptor protein, the autosomal recessive hypercholesterolemia 
(ARH) protein (Park et al., 2004). Some proteosome, metalloprotease and aspartic or 
lysosomal cysteine protease inhibitors showed that these enzymes were not involved in 
the degradation of the LDLr (Maxwell et al., 2005). Initial experiments suggested that 
degradation of the LDLr occurred at the cell surface prior to internalisation (Park et al., 
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2004), while later experiments indicated  that degradation occured subsequent to 
transport from the ER in a pH dependant organelle (Maxwell et al., 2005; Holla et al., 
2007). It was also shown that endocytosis of the LDLr is not needed for the receptor to 
be degraded by PCSK9 (Park et al., 2004; Maxwell et al., 2005; Holla et al., 2007), and 
PCSK9 does not degrade a recombinant secreted soluble LDLr (Holla et al., 2007), both 
results supporting the theory that degradation takes place in an intracellular compartment.  
 
Exogenously added PCSK9 however, was internalised into cells and degraded the LDLr 
pool (Lagace et al., 2006; Holla et al., 2007) independent of clathrin-coated pit formation 
(Holla et al., 2007) and independent of PCSK9 catalytic activity (Li et al., 2007a; McNutt 
et al., 2007; Schmidt et al., 2008). The conflicting data between various groups, where 
some results suggest that catalytic activity is required, while others suggest that catalytic 
activity is not required, needs further clarification. From the literature, it seems that 
autocatalytically inactive PCSK9 constructs (transfected into cells or injected into mice) 
are defective in LDLr degradation (Park et al., 2004; Maxwell et al., 2005; Benjannet et 
al., 2006; Homer et al., 2008), but those used in conjunction with the prodomain (as a 
secreted PCSK9) have showed degradation independent of activity (Li et al., 2007a; 
McNutt et al., 2007; Schmidt et al., 2008). This suggests that the prodomain is important 
for secreted PCSK9 in the internalisation and degradation of the LDLr.  
 
Degradation of the LDLr by secreted PCSK9 was shown to be dependent on the 
internalisation of the LDLr (Qian et al., 2007; Lagace et al., 2006), ARH, (in primary 
hepatocytes) and to some extent the LRP in mouse embryonic fibroblasts (Lagace et al., 
2006). This group also showed that PCSK9 can bind the extracellular domain of the 
LDLr by co-immunoprecipitation and ligand blots. Experiments using parabiosis (an 
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experiment which involves the sharing of plasma between 2 mice), showed that secreted 
PCSK9 in plasma transferred from one mouse to the next parabiotic mouse was able to 
reduce hepatic LDLr expression in the recipient mouse (Lagace et al., 2006). Fisher et al. 
(2007) showed that secreted PCSK9 lowered LDL uptake by the LDLr, that its binding 
was detected at neutral pH, as well as at endosomal pH where the binding affinity was 
150-fold higher, and that LDL reduced PCSK9 dependant LDLr degradation (Fisher et 
al., 2007). Because of this tight interaction at low pH, recycling to the surface is 
prevented and it is thought that the LDLr is rather targeted for lysosomal degradation. 
The region of the LDLr that binds PCSK9 to the LDLr was narrowed down to an EGF A 
repeat (Zhang et al., 2007; Kwon et al., 2008). It was also shown that after internalisation 
of PCSK9 by the LDLr, over time the LDLr was found in the early endosomes, late 
endosomes and lysosome. From the literature, the current understanding is that PCSK9 
can act on the LDLr at two points in the LDLr lifecycle: (i) in the secretory pathway, the 
LDLr can be targeted for degradation, and (ii) after secretion, PCSK9 can be internalised 
and targets the LDLr for degradation rather than recycling, Fig. 1.4 (Horton et al., 2007; 
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1.1.6 Mutations in the LDLr 
A mutation in the LDLr gene can result in the LDLr functioning sub-optimally or not at 
all, resulting in the inadequate clearance of plasma cholesterol. These mutations are 
typically called loss-of-function mutations. There are a number of mutations that can 
occur within the LDLr and these different mutations are classified into different groups 






















Figure 1.4: PCSK9 and LDLr degradation (adapted from Lambert et al., 2008). 
The normal trafficking and lifecycle of the LDLr is shown in pink. The two possible 
pathways for LDLr degradation is shown in red. PCSK9 may possibly act at two points in 
the LDLr pathway: (i) In the secretory pathway, the PCSK9 can target the LDLr for 
degradation, or (ii) as a secreted protein PCSK9 can be internalised and targets the LDLr for 
degradation rather than recycling. 
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Class 1 mutation (also called null allele) which results in no LDLr production (Goldstein 
et al., 1985). Mutations which result in the slow release of LDLr from the ER to Golgi 
are called Class 2 mutations or transport-defective mutants. These mutants are smaller in 
molecular weight, equivalent to the immature, unglycosylated form and are not expressed 
at the cell surface (Li et al., 2004). Class 3 mutations are binding-defective as the LDLr 
is expressed on the cell surface, but does not bind LDL, and therefore does not internalise 
LDL. Class 4 mutants, also expressed at the cell surface, bind LDL but do not internalise 
it since the mutation disrupts the internalisation signal. These mutants are thus termed 
internalisation-defective (Lehrman et al., 1985; Davis et al., 1986). Class 5 mutants are 
recycling-defective, and clear plasma LDL at a slower rate than normal due to the 
inability of the receptor to recycle to the membrane (Miyake et al., 1989). Cholesterol 
maintenance in these cells is dependent on the de novo synthesis of LDL receptors.   
Patients with any of the above defects in the LDLr present with a clinical condition, 
known as FH (Goldstein et al., 1985; Brown and Goldstein, 1986). Patients with a 
heterozygous mutation have a less severe form of FH, while those with a homozygous 
mutation in the LDLr, present with much higher levels of cholesterol, which leads to a 
quicker onset in the development of atherosclerosis, coronary artery disease (CAD) and 
fatal heart attacks or strokes in early adult life. Heterozygous mutations are common, 
occurring in 1 in 500 individuals, which highlights the importance of alleviating the onset 
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1.1.7 Autosomal Dominant Hypercholesterolemia (ADH) 
In addition to mutations in the LDLr gene, mutations in other genes also contribute to 
hypercholesterolemia, grouped as ADH (Rader et al., 2003). These are discussed briefly, 
below. 
 
1.1.7.1 Mutations in apoB-100  
Mutations in the apoB-100 protein result in the disruption of binding to the LDLr, and 
therefore prevent the uptake of LDL particles into the cell. These mutations can be 
present in the binding region or outside of the binding region. These mutations can affect 
binding to the receptor mildly or dramatically, depending on the type of mutation and 
affecting plasma cholesterol levels accordingly (Vrablik et al., 2001; Rader et al., 2003).  
 
1.1.7.2 Mutations in PCSK9 
Mutations in PCSK9 can fall into two groups, either loss or gain of function. Mutations 
of PCSK9 can also be classified as Class 1: null, Class 2: defective in processing, Class 
3: defective transport from ER, Class 4: altered stability or Class 5: altered affinity for 
the LDLr (Horton et al., 2007). Some gain of function mutants were shown to have 
higher LDLr degrading activity and thus lowered LDL uptake, which could be attributed 
to higher binding affinity to the LDLr (Lagace et al., 2006; Fisher et al., 2007). The loss 
of function mutations are of a protective type, preventing LDLr degradation and lowering 
LDL levels (Horton et al., 2007).  
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1.2 Ectodomain Shedding 
Ectodomain shedding is the proteolytic release of membrane-bound proteins into the 
extra-cellular milieu (Fig. 1.5) (Ehlers and Riordan, 1991; Hooper et al., 1997; Peschon 
et al., 1998; Arribas and Borroto, 2002; Mezyk et al., 2003). The group of enzymes 
responsible for the release of membrane-bound protein ectodomains are termed 




Many membrane proteins are shed as part of a post-translational event that is important 
in cell regulation. Examples are diverse ranging from receptors, receptor ligands and cell 
adhesion molecules to enzymes and other proteins. Furthermore these proteins can be of 
Figure 1.5: The process of ectodomain shedding (adapted from 
Black, 2002). 
The membrane protein is solubilised through proteolysis and release of the 
ectoprotein by a sheddase.  




Full length membrane 
bound protein 
Soluble ectoprotein  
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either type I or II membrane proteins, with the N-terminus facing extracellularly or 
intracellularly, respectively (Ehlers and Riordan, 1991; Hooper et al., 1997). A variety of 
functions have been attributed to ectodomain shedding, depending on the proteins 
involved (Peschon et al., 1998; Arribas and Borroto, 2002; Mezyk et al., 2003; Rebeck et 
al., 2006; Edwards et al., 2008). In the case of some cytokines, these become soluble 
factors that carry out functions elsewhere, either on the same cell (known as autocrine 
signaling) or at neighbouring cells (known as paracrine signaling). In the case of cell 
surface receptors or ligands involved in signaling, ectodomain release can lead to down 
regulation and inhibit signaling. The generation of soluble receptors could also serve to 
sequester ligands by binding to it (Rebeck et al., 2006). Ectodomain shedding also 
functions as an initial step in cell signaling, to promote the release of the intracellular 
domain.  Shedding of some proteins such as transforming growth factor-α (TGF-α), has 
also been shown to be important in the development of the mammalian embryo (Peschon 
et al., 1998), while aberrant shedding plays a major role in some disease incidences such 
as the overproduction of soluble tumour necrosis factor-α (TNF-α) in arthritis and the 
pathological processing of amyloid precursor protein (APP) in Alzheimer’s disease 
(Hooper et al., 1997). Shedding of most proteins is sensitive to hydroxamate based 
inhibitors, suggesting that the metalloproteases are the key family of enzymes 
responsible for this event (Arribas et al., 1996).  
 
Most sheddases belong either to a distintergrin and metalloprotease (ADAM) or the 
matrix metalloprotease (MMP) family (Arribas and Borroto, 2002; Chow and Fernandez-
Patron, 2007), the former contributing a major role in the shedding of proteins (Huovila 
et al., 2005). Since the first ADAM sheddase was isolated, 17 others of a potential of 33 
were identified to have shedding activity (Chow and Fernandez-Patron, 2007). Shedding 
  18 
of proteins occurs at a constitutive rate, but can be enhanced with the addition of phorbol 
ester, a stimulator of the protein kinase C (PKC) pathway (Arribas and Borroto, 2002) 
which may lead to the activation of proteases involved in shedding (Ehlers and Riordan, 
1991; Black, 2002). Ongoing studies on TNF-α converting enzyme (TACE) the first 
sheddase to be identified (Black et al., 1997; Moss et al., 1997) and other sheddases 
contribute to the understanding of the requirements for ectodomain shedding for the 
benefit of targeting excessive or aberrant shedding. 
 
1.2.1 Soluble counterparts of LDLr family members 
A few members of the LDLr family have also been found to have soluble counterparts, 
some of which have either been found in mammalian cell culture, human urine and/or 
human plasma. These members include the LDLr (Begg et al., 2004; Molina et al., 2007), 
ApoER2 (Hoe and Rebeck, 2005; Rebeck et al., 2006), LRP-1 (Quinn et al., 1997), 
megalin (glycoprotein 330) (Kounnas et al., 1993) and vLDLr (Marlovits et al., 1998b).  
 
1.2.1.1 Soluble LRP-1 
Soluble LRP-1 was isolated from human plasma by ligand affinity purification (Quinn et 
al., 1997; Quinn et al., 1999). The purified soluble LRP was approximately 500 kDa 
(corresponding to the α-chain of LRP-1), and was detected by RAP ligand blots as well 
as two different antibodies specific to the α-chain of LRP. Similar methods were used to 
detect the 85 kDa β-chain of LRP-1. It was suggested that a fragment of the β-chain 
could be present, but not detected by the antibody to the C-terminus. No soluble LRP 
was found in cultured HepG2 cells and human fibroblasts, while it was found in cultured 
rat hepatocytes (Quinn et al., 1997). Further characterisation of soluble LRP showed that 
an antibody to the extra cellular portion of the β-chain could detect a truncated form 
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present in the affinity purified sample (Quinn et al., 1999). Release of soluble LRP could 
be inhibited by a hydroxamic acid compound, INH-3855-PI, a broad range 
metalloprotease inhibitor. Membrane type 1 matrix metalloprotease (MT1-MMP) is 
involved in the shedding of the LRP-1 (Rozanov et al., 2004). To investigate the 
possibility of the β-secretase (BACE) as a potential sheddase responsible for the cleavage 
of the extracellular domain of LRP, cells were analysed for the co-localisation and co-
immunoprecipitation of BACE and LRP (von Arnim et al., 2005). In addition, the LRP 
was also shown to undergo γ-secretase cleavage by the release of the intracellular domain 
(ICD) after ectodomain release (May et al., 2003). The region of interaction was shown 
to be in the ICD.  The presence of BACE increased shedding of LRP, while inhibitor 
studies and the presence of small interference RNA (siRNA) against BACE, showed a 
decrease in LRP shedding (von Arnim et al., 2005).   
 
1.2.1.2 Soluble megalin 
A soluble fragment of megalin was first purified from urine (Kounnas et al., 1993). 
Megalin was shown to undergo ectodomain shedding with subsequent regulated 
intracellular proteolysis and release of the ICD of the C-terminal fragment (Zou et al., 
2004b; Biemesderfer, 2006). The function of ligand ectodomain shedding and release of 
megalin is thought to play a role in the activation of genes in the metabolism of that 
ligand.   
 
1.2.1.3 Soluble ApoER2 
The ectodomain release of cell surface ApoER2 was sensitive to metalloprotease 
inhibition and increased in the presence of ligand and in the presence of PMA (Hoe and 
Rebeck, 2005). In addition, like the LRP, ectodomain cleavage of the ApoER2 results in 
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the γ-secretase dependent release of the ICD, which may function in signaling pathways 
(May et al., 2003; Hoe and Rebeck, 2005; Rebeck et al., 2006). 
 
1.2.1.4 Soluble LDLr and vLDLr 
It must be highlighted that the ectodomain shedding of the LDLr is a phenomenon 
different to the PCSK9-mediated degradation, since degradation of the LDLr by PCSK9 
was shown not to occur in fibroblasts (Horton et al., 2007) and Chinese hamster ovary 
(CHO) cells (Park et al., 2004; Horton et al., 2007) and soluble LDLr was not detected in 
medium of cells expressing PCSK9 (Maxwell et al., 2005). These data suggest that 
PCSK9 does not mediate release of LDLr into the external surroundings. 
 
Soluble LDLr was shown to be produced in response to human rhinovirus (HRV) 
infection (Hofer et al., 1994). It was able to bind to the virus HRV-2 as demonstrated by 
[35S] methionine-labelled virus ligand blotting and therefore prevent its uptake into the 
cell. Conversely, membrane-bound LDLr binds HRV-2, and internalises it. In the same 
study, binding of the HRV-2 is attenuated in the presence of iodinated LDL, thus further 
implicating the LDLr in this binding. In FH cells, however, LRP was found to be the 
receptor that endocytoses HRV-2 in the absence of LDLr.  
 
Recombinant soluble LDLr (comprising the ligand binding domain) was shown to inhibit 
rhinovirus infection in HeLa cells by causing viral aggregates (Marlovits et al., 1998c). 
Further analysis using ligand blots on different lengths of recombinant, purified soluble 
LDLr showed that it was able to bind HRV-2 (Marlovits et al., 1998a). However, only 
constructs containing more than two repeats of the ligand binding domain were able to 
elicit anti-viral activity. 
  21 
Like the LDLr, the vLDLr was also implicated to undergo shedding in response to HRV 
infection (Marlovits et al., 1998b). A 84 kDa band, representing the vLDLr bound to 
HRV-2 and antibodies against vLDLr in a calcium dependent manner (Hofer et al., 1992; 
Marlovits et al., 1998b).The function of soluble vLDLr formation was suggested to be 
important for the neutralisation of rhinovirus, thus preventing the penetration of viral 
RNA (Nicodemou et al., 2005). 
 
A 28 kDa protein, identified to be a soluble LDLr N-terminal fragment by protein 
microsequencing and antibody studies, was shown to protect mammalian cells from 
vesicular stomatis viral (VSV) infection (Fischer et al., 1993). This N-terminal fragment 
is produced after induction by interferon (IFN), but experiments also showed that the 
soluble LDLr fragment added before or after viral incubation could inhibit viral titre, 
independent of IFN induction. It was found that inhibition does not occur through 
attenuation of the binding of the virus to the cell associated receptor. This indicates that 
the soluble LDLr fragment can act as an antiviral protein, but the mode of action is not 
known. The LDLr however is not the sole antiviral protein shed in response to IFN, as 
FH fibroblasts (LDLr null) were able to reduce viral titre by IFN induction (Fischer et al., 
1993). 
 
A truncated 140 kDa soluble form of the LDLr was found in the medium of cultured 
human skin fibroblasts as well as CHO cells over-expressing the receptor (Begg et al., 
2004). The soluble LDLr was only able to bind antibodies directed to the N-terminal 
ectodomain, but not antibodies directed to the C-terminal tail, suggesting that the N-
terminus had been released by ectodomain shedding. To test the possibility that the 140 
kDa soluble receptor is a product of proteolysis and not gene splicing, cells were 
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radioactively labelled with [35S] methionine and a 140 kDa band was only present in the 
medium and not seen in the cells, which provided further evidence that the LDLr is shed 
from the membrane. Moreover, the LDLr undergoes increased shedding in the presence 
of phorbol myristate acetate (PMA), and decreased proteolytic release in the presence of 
TNF-α Protease Inhibitor (TAPI), a common feature amongst shed proteins (Arribas et 
al., 1996). The change in size of the membrane-bound form to that of soluble receptor is 
also consistent with shedding occuring in the juxtamembrane stalk region of the LDLr 
(Begg et al., 2004).  
 
In order to elucidate the sheddase(s) involved in the shedding of the LDLr, a range of 
inhibitors were tested on cells expressing LDLr (Begg et al., 2004). Compounds tested 
such as serine, cysteine and aspartic protease inhibitors showed no reduction in shedding. 
EDTA and EGTA inhibited shedding of the LDLr by 33 % and 50 %, respectively, while 
the inhibitor that showed the highest reduction in shedding was the hydroxamate-based 
inhibitor, TAPI. TAPI used at a concentration of 10 µM was capable of inhibiting LDLr 
shedding by 90 %. These data implicate metalloprotease activity in the ectodomain 
shedding of the LDLr. TACE is involved in the shedding of a number of membrane-
bound proteins (which will be discussed further), and is a possible candidate in the 
shedding of the LDLr as a cell line deficient in TACE activity showed that conditioned 
medium from TACE deficient cells produced less soluble LDLr, in addition to other 
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1.2.2 Ectodomain shedding and the glycosylation states of LDLr family members  
When the LDLr was expressed in a CHO cell line deficient in O-glycosylation, it was 
found to be shed into the medium more rapidly than LDLr expressed in the presence of 
various sugars (Kozarsky et al., 1988). The vLDLr and ApoER2 occur in two forms, an 
O-glycosylated form and one lacking the O-glycosylated domain (Magrane et al., 1999; 
Rebeck et al., 2006). Studies on the function of the two forms of vLDLr showed that the 
presence of the O-glycosylated domain hampered shedding of the vLDLr, as constructs 
that did not have the O-glycosylated region were shed more rapidly from the membrane 
(Magrane et al., 1999). The same effect was seen when vLDLr was expressed in O-
glycosylation deficient cells, and it was thought that the O-glycosylated domain, or 
glycans present, restricted the availability of the cleavage site residues. As with the 
vLDLr, it was found that increased shedding of hypoglycosylated forms of LRP and 
ApoER2 occurs (May et al., 2003). The role of glycosylation states in different tissues 
may result in different shedding rates of LRPs and possibly other members of the LDLr 
family as well.
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1.3 TACE 
Two independent groups cloned and purified TACE in 1997 and identified this enzyme 
as the first sheddase to cleave the cytokine, pro-TNF to mature TNF (Black et al., 1997; 
Moss et al., 1997). TACE is also known as ADAM 17 (Killar et al., 1999). TACE is a 
zinc dependent metalloprotease and is a member of the ADAMs family, which is part of 
the metzincin family that includes snake venom metalloproteases (SVMPs) and MMPs 
(Killar et al., 1999; Mezyk et al., 2003). ADAMs play a role in fertilisation, functioning 
of the immune systems and other processes (Mezyk et al., 2003), whereas MMPs 
function in the degradation of extracellular matrix proteins in addition to other proteins 
(Huovila et al., 2005).  
 
 
The structure of TACE is divided into a prodomain, a zinc-binding catalytic domain, a 
cysteine-rich disintegrin domain, a transmembrane domain and a cytoplasmic domain 
(Fig. 1.6) (Black, 2002; Li et al., 2007b). TACE is a type I membrane protein and is 
translated as a zymogen, as a result TACE occurs in two forms: a full length form 
Figure 1.4 Domain structure of TACE zymoygen (upper) and 
mature TACE (lower) [adapted from Li et al., 2007 (b)]. 
Pro: prodomain, Cat: catalytic domain, CRD: cysteine-rich disintegrin 
domain, TM:  transmembrane domain and CT: cytoplasmaic domain. 
The open circle represents the active site in the catalytic domain. 
 
Pro  Cat CRD TM CT 
Cat CRD TM CT 
672 215 475 18 695 827 
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containing the prodomain and a mature, active form which has the prodomain removed 
(Schlondorff et al., 2000). The role of the disintegrin domain in TACE was not known 
previously, but the first evidence of its function was provided by the demonstration of an 
interaction of the cysteine-rich domain of TACE with that of the integrin receptor, 
integrin α5β1 (Bax et al., 2004).  
 
1.3.1 Function of TACE 
TACE knock-out (KO) mice indicated that TACE and shedding are important in the 
development of the embryo as mice deficient in TACE died at birth and a few that 
survived, did not live for longer than 3 weeks (Peschon et al., 1998). These mice also had 
characteristics that are phenotypically similar to TGF-α KO mice, indicating that TACE 
was also important for the shedding of TGF-α. However, TGF-α KO mice do not die at 
birth indicating that TACE plays a prominent role in shedding of substrates important in 
development.  
 
Soluble proteins such as cytokines and receptors released by TACE are important in the 
functioning of the immune system. TACE was shown to be involved in the shedding of 
L-selectin, interleukin (IL)-1R-II, both the TNF-α receptors [p55TNF receptor (TNFRI) 
and p75TNF receptor (TNFRII)], TNF-related activation-induced cytokine (TRANCE), 
in addition to TNF-α (Peschon et al., 1998; Lum et al., 1999; Reddy et al., 2000).  
 
Some EGFR ligands are also dependent on TACE-mediated shedding. These include 
TGF-α, heparin binding EGF (HB-EGF), amphiregulin and epiregulin (Peschon et al., 
1998; Sahin et al., 2004). Another substrate of TACE important in development, is the 
growth hormone receptor (GHR) involved in the stimulated production of GH binding 
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protein (GHBP) (Zhang et al., 2000). Another EGFR family member HER4,  involved in 
the development of organs, is also dependent on TACE activity  for cleavage release (Rio 
et al., 2000).  
 
TACE possesses α-secretase-like activity in the cleavage of APP, while BACE cleaves at 
the β site in the generation of amyloid β peptide (Aβ) in Alzheimer’s disease (Buxbaum 
et al., 1998; Asai et al., 2003; Allinson et al., 2004). Cleavage by TACE prevents the 
generation of the amyloidogenic peptide since it cleaves within the Aβ peptide. TACE 
and BACE do not compete in the proteolysis of APP under normal conditions (Kim et 
al., 2008). Notch-1 undergoes similar processing as APP in a TACE dependent manner 
(Brou et al., 2000; Delwig and Rand, 2008). Ligand dependent shedding of Notch-1 
releases an intracellular domain, which translocates to the nucleus and acts as a 
transcription factor of genes important in development (Edwards et al., 2008).  
 
The severe-acute respiratory syndrome-coronavirus (SARS-CoV) increased TACE 
activity for the release of the SARS-CoV receptor, angiotensin converting enzyme 2 
(ACE) 2  (Lambert et al., 2005). The spike protein of the virus was able to induce TACE-
mediated shedding of ACE 2 and TNF-α. In addition, the cytoplasmic tail of ACE 2 and 
the presence of TACE were needed for viral entry suggesting that signals resulting from 
TACE-mediated ACE 2 shedding lead to tissue damage (Haga et al., 2008).  
 
While a number of substrates exist for TACE, it was also shown that in TACE KO cells, 
the absence of TACE did not affect the shedding of ACE (Sadhukhan et al., 1999), which 
indicated that other shedasses(s) are responsible for the ectodomain release of that 
protein. Mice deficient in TACE presented with normal serum levels of ACE. Using 
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antisense oligonucleotides, TACE as well as ADAM 10 were ruled out as sheddases 
responsible for the shedding of ACE (Allinson et al., 2004). In addition, recombinant 
ADAM 10 did not cleave an ACE peptide spanning the cleavage site of the stalk region 
(Lammich et al., 1999). 
 
1.3.2 Regulation of TACE 
TACE remains inactive by the co-ordination of a sulphydryl group from a cysteine 
present in the N-terminal prodomain to the zinc in the active site forming a “cysteine 
switch” (Moss et al., 1997). Cleavage by a proprotein convertase (PC) furin within the 
Golgi, or post-Golgi releases a mature active form which is expressed on the surface of 
cells (Moss et al., 1997; Schlondorff et al., 2000; Endres et al., 2003)..  
 
While the removal of the prodomain is essential for TACE activity (Moss et al., 1997; 
Milla et al., 1999), the presence of the prodomain is required for transport of TACE to 
the membrane, as constructs without the prodomain are degraded. Studies using the 
purified prodomain as an inhibitor against TACE constructs, suggested that the presence 
of the distintegrin domain may facilitate in the furin dependent removal of the 
prodomain, while the cysteine present in the prodomain might prevent degradation 
(Gonzales et al., 2004). When a prodomain construct containing a mutation that disrupts 
cysteine switch formation showed the same inhibitory potential as wild-type, it was 
concluded that the cysteine switch is not required for inhibitory activity. To study the 
role of the cysteine switch in TACE further, Buckley et al., identified the amino-terminus 
of TACE to have inhibitory activity in the absence of the cysteine switch, as the construct 
used in the study increased TACE-mediated shedding of TNFR II (Buckley et al., 2005).  
 
  28 
Despite the high sequence homology between ADAM 10 and TACE, replacing the 
TACE catalytic metalloprotease region with that of ADAM 10 does not result in the 
production of a functional construct (Reddy et al., 2000). Since a point mutation in the 
cysteine-rich disintegrin domain inactivated ectodomain shedding, it was suggested that 
this region is also important in regulating TACE (Li and Fan, 2004). Studies on the 
transmembrane domain of TACE showed that a secreted soluble TACE construct lacking 
the transmembrane was defective in cell-based shedding assays. A transmembrane-free 
TACE construct that was anchored to the membrane did not shed TGF-α, TNF-α and L-
selectin (Li et al., 2007b). These data indicate that the transmembrane is important for 
anchoring TACE, in addition to other roles important for regulation.  
 
Shedding of TNF-α, TGF-α and L-selectin at the constitutive level occurs via the p38 
mitogen-activated protein (MAP) kinase pathway, while the EGF or PMA stimulated 
shedding occurs through the ERK-2 MAP kinase pathway (Fan and Derynck, 1999). 
Zhang et al., showed that reactive oxygen species (ROS) produced in response to PMA is 
the agent that increases TACE activity by attacking the sulphydral cysteine in the 
prodomain (Zhang et al., 2001).  
 
TACE is phosphorylated in response to stimulation by PMA (Fan et al., 2003) and 
gastrin releasing peptide (Zhang et al., 2006). However, cleavage by TACE in a cell 
system occurs by membrane-anchored TACE independent of a cytoplasmic domain 
(Reddy et al., 2000; Doedens et al., 2003; Fan et al., 2003; Li and Fan, 2004; Edwards et 
al., 2008).  
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PMA increased cellular TACE activity on the cell surface or in a compartment, without 
the associated increase in TACE expression levels (Doedens et al., 2003). It was 
suggested that prolonged exposure to PMA leads to down regulation of mature TACE on 
the cell surface by the degradation of TACE, conceivably as a regulatory mechanism 
(Doedens and Black, 2000). Enderes et al., showed that the PMA-mediated down-
regulation only affects TACE and not ADAM 10. Furin transfected into furin deficient 
cells was tested for degradation of TACE in response to PMA (Endres et al., 2003). No 
degradation of mature TACE was seen, suggesting that furin is not responsible for the 
PMA-mediated degradation of TACE.  
 
Thus, the role of the cytoplasmic domain in the regulation of TACE and the mechanism 
by which PMA up-regulates TACE is still not clear, since data showed that TACE is 
phosphorylated in the cytoplasmic tail in response to PMA, while constructs lacking the 
cytoplasmic domain are still active and responsive to PMA stimulation (Reddy et al., 
2000; Doedens et al., 2003; Edwards et al., 2008). 
 
N-arginine dibasic convertase [Nardilysin, (NRDc)] binds to and increases TACE 
activity for the shedding of HB-EGF, APP and TNF-α. Addition of phorbol enhances the 
interaction and release of soluble HB-EGF. The catalytic activity of NRDc is not 
required for increased shedding of HB-EGF, APP and TNF-α by TACE. Enhancement of 
shedding by NRDc affects TACE-, ADAM 9- and ADAM 10-mediated shedding of 
APP, while it was shown not to affect TACE- and ADAM 10-mediated shedding of 
TNF-α (Hiraoka et al., 2008). 
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Under different conditions, different sheddases are responsible for the shedding of some 
proteins. For example, in the case of the prion protein TACE is responsible for up-
regulated shedding whereas ADAM 10 is the sheddase responsible for constitutive 
shedding (Vincent et al., 2001). Another example is TNF-α, where TACE is the sheddase 
responsible for phorbol stimulated shedding, while the other ADAMs such as ADAM 9 
and 10 are involved in constitutive shedding (Zheng et al., 2004). Furthermore, ADAM 9 
and ADAM 10 KO experiments suggest that these are not the only sheddases responsible 
for constitutive shedding. TACE seems to be responsible for nearly 90 % of stimulated 
shedding of proteins studied, while other sheddases are important for either constitutive 
or stimulated shedding (Huovila et al., 2005).  
 
1.3.3 TACE substrate specificity 
The use of TACE KO systems have revealed a number of unrelated membrane-bound 
proteins, either of type I or II, that are dependent on TACE cleavage (Peschon et al., 
1998; Reddy et al., 2000; Vincent et al., 2001; Guo et al., 2002; Mezyk et al., 2003; 
Huovila et al., 2005; Reiss and Saftig, 2008). Due to the apparent lack of specificity, 
factors that influence substrate recognition for TACE remain unclear, as TACE cleaves 
unrelated sequences thus resulting in different cleavage sites. Although there does not 
seem to be a specific recognition sequence, an Ala-Val bond seems to be preferred in 
some instances (Black et al., 2003). Even with different cleavage sites found for TACE 
substrates, there exists specificity for at least the TNF-α peptide. In this case, peptide 
assays showed that cleavage by TACE did not occur when the Ala was replaced with an 
Ile in the TNF-α peptide, while replacing it with a Val/Gly reduced cleavage by more 
than 90 % (Black et al., 2003). Cleavage of the peptide was reduced to 30 % when the 
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Val was replaced with Leu/Ile. Some of the cleavage sites of TACE substrates are 
highlighted in Table 1.1. 
 
Table 1.1: Cleavage sites of peptides by TACE (adapted from Mezyk et al, 2003 and Black 
et al, 2003). 
Protein/Peptide Cleavage site 
TNF-α PLAQAV ↓  RSSS 
TGF-α N-terminal peptide   PVAAA ↓  VVSHF 
TGF-α C-terminal peptide    ADLLA ↓  VVAAS 
Amphiregulin N-terminal 
peptide 
SVRVEQ ↓ VVKPPQ 
Amphiregulin C-terminal 
peptide 
ERCEGEK ↓ SMKTHS 
Epiregulin N-terminal 
peptide  
NPRVAQ  ↓VSITKC 
TNFR-I      PQIEN  ↓ VKGTE 
TNF-II    APGAV  ↓ HLPQP 
IL-6R-α    SLPVQ  ↓ DSSSV 
L-selectin   QKLDK  ↓ SFSMI 
APP   VHHQK ↓  LVFFA 
 
While TACE activity is implicated in a variety of substrates, the stalk peptides and their 
length are important factors in the cleavage of at least TNF-α and L-selectin, since stalk 
regions with the cleavage site present but without the adjacent sequences were not 
cleaved (Zheng et al., 2004, Tsakadze et al., 2006). In addition, the importance of the 
stalk sequence was indicated by the substitution of TACE substrate stalk sequences into 
non-TACE substrates allowed the ectodomain release of the non-shed proteins (Tsakadze 
et al., 2006).  
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1.3.4 Other sheddases that cleave TACE substrates 
Other recombinant ADAMs such as ADAM 9 (Roghani et al., 1999) and ADAM 10 
(Rosendahl et al., 1997; Hinkle et al., 2003) are able to cleave TNF-α peptides in vitro. 
ADAM 10 also cleaves a membrane form of TNF-α (Rosendahl et al., 1997) and cleaves 
the prion protein under constitutive conditions (Vincent et al., 2001). In the cleavage of 
APP, ADAM 9 and ADAM 10 also act in a α-secretase-like manner similar to TACE 
(Asai et al., 2003; Deuss et al., 2008). Shedding data from TACE, ADAM 9 and ADAM 
10 KO cell lines suggested that the ADAMs function as a team in the cleavage of APP, 
and compensate for another in the absence of one ADAM. TACE KO studies indicated 
that the major sheddase for Notch-1 processing is ADAM 10, and that TACE KO mice 
do not display phenotypes associated with defects in Notch-1 signaling, suggesting a 
minor role for TACE in Notch processing physiologically. Additional TACE substrates 
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Table 1.2: Table depicting different sheddases that act on TACE substrates. 
Sheddase ADAM name TACE substrate  
MS2 ADAM 8 TNF-α (Amour et al., 2002; Naus et al., 2006), APP, 
kit ligand 1 (KL-1) (Amour et al., 2002), TGF-α, L-
selectin (Naus et al., 2006) ADAM 8 does not cleave 
KL-1 (Naus et al, 2006) TRANCE (Naus et al., 2006) 
MDC-9/ Meltrin-γ ADAM 9 TNF-α peptide (Roghani et al., 1999), HB-EGF (Izumi 
et al., 1998), APP (Asai et al., 2003), Collagen XVII, 
epiregulin, KL-1 (Roghani et al., 1999; Amour et al., 
2002) 
Kusbanian  ADAM 10 TNF-α peptide (Rosendahl et al., 1997; Hinkle et al., 
2003), cellular prion protein (Vincent et al., 2001), 
Desmoglein-2, activated leukocyte cell adhesion 
molecule (ALCAM) (Bech-Serra et al., 2006), APP 
peptide (Lammich et al., 1999), APP (Asai et al., 2003; 
Allinson et al., 2004), TGF-α (Hinkle et al., 2003), 
HB-EGF (Lemjabbar and Basbaum, 2002), CD44, 
Notch, Collagen XVII [no cleavage of HB-EGF and 
KL-1 (Amour et al., 2002)] 
Meltrin-α ADAM 12 HB-EGF (Asakura et al., 2002), epiregulin  
MDC-15 ADAM 15 TGF-α, epiregulin, amphiregulin  
Meltrin-β ADAM 19 TNF-α (Zheng et al., 2004), TNF-α peptide, 
TRANCE, KL-1 (Chesneau et al., 2003)  
 ADAM 33 Peptides of APP, KL-1, TRANCE, TNF-α (Zou et al., 
2004a) 
MMP-1 N/A TNF-α peptide (Mohan et al., 2002; Jin et al., 2002) 
MMP-3 N/A HB-EGF (Suzuki et al., 1997b) 
MMP-7 N/A TNF-α peptide (Mohan et al., 2002), TNF-α (Haro et 
al., 2000), HB-EGF (Yu et al., 2002) 
MMP-9 N/A TNF-α peptide (Mohan et al., 2002; Jin et al., 2002) 
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TACE is the most promiscuous of identified sheddases as it is responsible for the 
shedding of a larger number of unrelated proteins, including cytokines, growth factors, 
receptors, adhesion molecules and some other proteins when compared to other 
sheddases (Mezyk et al., 2003; Huovila et al., 2005; Reiss and Saftig, 2008). Redundancy 
between members of the ADAMs family exists, as some can take over the function when 
the other member is absent. This can also be seen from Table 1.2 as a number of ADAMs 
and some MMPs are also able to cleave TACE substrates (Chow and Fernandez-Patron, 
2007). TACE cleaves many substrates, some more efficiently than others, but the role it 
plays in the cleavage of some proteins is not known. In conclusion, it is evident that 
sheddases preferentially act on a particular substrate while still being able to cleave 
others. In addition, there are substrates which can be cleaved by different sheddases and 
provides evidence that it is possible for other ADAMs to take over shedding of proteins 
in the absence of a particular ADAM, depending on the stimulation or tissue type or type 
of experiment performed (Chow and Fernandez-Patron, 2007). 
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Thesis outline 
 
The aim of this thesis was to investigate the cellular machinery involved in the 
ectodomain release of the LDLr, which was previously shown to undergo regulation in 
the presence of phorbol esters and the hydroxymate inhibitor, TAPI. (Begg et al., 2004) 
An objective of this thesis was to sub clone the LDLr into a suitable expression vector 
and to mutate the LDLr from wild-type to the internalisation defective mutants, 792-
LDLr or JD-LDLr (discussed in Chapter 3). These mutant receptors have been shown to 
be shed more efficiently than the wild-type receptor and were of interest as these 
mutations occur in some Familial Hypercholesterolemia cases. An initial approach in this 
thesis was to construct a green fluorescent protein (GFP)-tagged LDLr to assess soluble 
LDLr levels released into medium of cultured cells (discussed in Chapter 4). A 
proteomics study implicated as a TACE candidate sheddase of the LDLr (Guo et al., 
2002). To determine the extent of TACE involvement as well as the possible role of other 
sheddases in the release of the ectodomain of the LDLr, the shedding profiles of the 
LDLr constructs were investigated in wild-type and TACE deficient mouse fibroblasts 
and wild-type and TACE deficient CHO cells (discussed in Chapter 5). In addition, LDLr 
shedding was assessed in the presence of a phorbol and TAPI to assess stimulated 
shedding and the inhibition of shedding in the absence and presence of TACE. Lastly, it 
was of interest to establish whether soluble LDLr was present in human plasma to show a 
physiological relevance of LDLr ectodomain release (discussed in Chapter 6).   
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Chapter 2: 




The vector, pcDNA3.1 (H)- was purchased from Invitrogen. The hrGFP Vitality vector 
was obtained from Stratagene Vitality. The pLDLr-2 vector was obtained from M. 
Begg (Yamamoto et al., 1984; Begg et al., 2004). Primers were purchased from 
Integrated DNA Technologies through Whitehead Scientific or from Inqaba Biotech 
Biotechnical Industries, South Africa. Pimer sequences for the GFP constructs are shown 
in Appendix I [Fig. I.]. Primer sequences for the site-directed mutagenesis reactions are 
shown in Appendix I [Fig. II.]. The restriction enzymes Xba I, Hind III, Not I, Cla I, Bgl 
II, Kpn I, Bam HI, Eco RI, Nhe I, Aat II, Eco RV, Sma I and the appropriate buffers were 
purchased from Roche. The restriction enzyme Bfi I and buffer were purchased from 
Fermentas Life Sciences. The Pfu polymerase, dNTP mix, and Dpn I and T4 DNA ligase 
were purchased from Promega. The transfection kit Profection Mammalian 
Transfection System was purchased from Promega. Hygromycin was purchased from 
Sigma Aldrich Company Inc. 
 
2.1.2 Cell lines 
The wild-type and TACE KO mouse fibroblasts were obtained from R. A. Black 
(Amgen, USA). The CHO A7 cells were obtained from M. J. Begg (Begg et al., 2004). 
The CHO M2 cells were obtained from J. Arribas (Borroto et al., 2003).  
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Table 2.1: Table depicting the different properties of the cell lines used in this study 




Wild-type mouse fibroblasts yes yes 
TACE-/- mouse fibroblasts yes no 
CHO A7 no yes 
CHO M2 yes no 
 
2.1.3 Antibodies 
The rabbit polyclonal LDLr antibody (Research Diagnostics, Inc.), the goat polyclonal 
LDLr antibody (R & D systems), the mouse monoclonal LDLr (C7) antibody (Research 
Diagnostics, Inc.), the polyclonal hrGFP Vitality antibody (Stratagene), the anti-TACE 
IgG (Abcam), the anti-ADAM 9 IgG (Oncogene, Calbiochem), the ADAM 10 IgG 
(Oncogene, Calbiochem), the anti-rabbit IgG (Amersham Biosciences, Sweden), the anti-
goat IgG (R & D systems), and the anti-mouse IgG (Amersham Biosciences, Sweden), 




2.2.1 Recombinant deoxyribonucleic acid (DNA) technology 
2.2.1.1 Polymerase chain reaction (PCR) 
PCR was performed with 1.5 units of pfu polymerase (Promega), 500 ng of DNA 
template, 0.8 µg of each primer, 200 µM dNTP mix (Promega), 1 X pfu buffer and water 
up to a final volume of 50 µl. The following parameters for PCR reactions were used: 
DNA was denatured at 94°C for 4 minutes for 1 cycle. This was followed by 30 cycles of 
amplification with a denaturing step of 1 minute at 92°C, annealing for 2 minutes at the 
annealing temperature, and an elongation at 72°C for 2 minutes.  A final elongation for 1 
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cycle was carried out at 72°C for 5 minutes. The reaction was held at 4°C overnight. All 
the preparations for the amplifications including the addition of polymerase were done on 
ice and reactions were performed in the Hybaid DNASprint PCR apparatus. A 10 µl 
aliquot of the reaction was analysed by the addition of 1 µl of 6 X loading dye (Appendix 
II) and separation of products on 0.8 % (w/v) agarose or  poly-acrylamide gel 
electrophoresis (PAGE)(12 % gel). 
 
2.2.1.2 Agarose Gels 
0.8 % (w/v) Agarose in 1X TBE (89 mM Tris base, 89 mM boric acid, 2 mM EDTA) 
containing ethidium bromide (0.2 mg/ml). Electrophoresis was performed at 70 volts for 
approximately 1 hour in 1 X TBE buffer with 0.2 mg/ml ethidium bromide. DNA bands 
in agarose gels were visualised by exposure to ultra violet at 260 nm and photographed. 
 
2.2.1.3 PAGE gels 
DNA was separated on PAGE (12 % gel) made up with 1 X TBE, 0.001 % ammonium 
persulphate (AMPS) and 10 µl Tetramethylethylenediamine (TEMED). Electrophoresis 
was performed at 50 volts. To visualise the DNA, gels were stained by silver staining in 
0.1 % AgNO3 for 10 min, followed by fixing and developing in 1.5 % NaOH and 1.5 % 
formaldehyde.   
 
2.2.1.4 Restriction Enzyme Digests 
The enzymes were used with compatible buffers. 10 units each of restriction enzyme, 0.5 
-1 µg DNA, 2 µl buffer and sterile water up to a final volume of 20 µl were used per 
reaction. All the preparations, including the addition of enzymes were done on ice. All 
digests were incubated at 37°C for 2 hours, except for Sma I, which was incubated at 
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25°C for 1 hour, before the addition of the second enzyme and digested further for an 
hour. All reactions were stopped with the addition of 6 X loading dye except for Bfi I, 
where reaction was stopped with the company supplied loading dye and inactivation at 
65°C for 10 minutes.  
 
2.2.1.5 Site Directed Mutagenesis 
 
The site-directed mutagenesis was adapted from the Stratagene Quickchange method 
(Fig. 2.1). Briefly, this method entails designing a set of primers that are complementary 
Figure 2.1: Schematic diagram representing the Dpn I site-directed 
mutagenesis approach, taken from Stratagene Quickchange. 
Step 1: Plasmid with gene of interest to be mutated. 
Step 2: The plasmid is denatured and annealed with mutagenic primer containing 
mutation. Pfu DNA polymerase extends the sequence, resulting in in nicked circular 
strands. 
Step 3: The methylated non-mutated DNA is digested with Dpn I.  
Step 4: The DNA is transformed and E.coli repairs the nicks in the mutated plasmid.  
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to the sense and anti-sense of the template DNA strands and that have the mutation of 
interest as well as a silent mutation to introduce a restriction enzyme site [Appendix I, 
Fig. II.]. The restriction enzyme site was introduced so that clones could be screened for 
the presence of the mutation. After the mutagenesis reaction, the PCR product was 
digested with Dpn I to remove non-mutated parental DNA. The reaction was transformed 
into competent E.coli JM109 cells.  
 
PCR was performed with 1.5 units of Pfu polymerase (Promega), 50 ng of DNA 
template, 0.8 µM of each primer, 400 µM dNTP mix (Promega), 1/10 volume of buffer 
(final 1 X) and water up to a final volume of 50 µl was used for the mutagenic reaction. 
The following parameters for PCR reactions were used: The DNA was denatured at 94°C 
for 5 minutes for 1 cycle. This was followed by 16 cycles of amplification with a 
denaturing step of 30 seconds at 92°C, annealing for 30 seconds at the annealing 
temperature, and an elongation step at 72°C for 16 minutes.  The elongation step was 2 
minutes per kilo base pairs (kbp) of DNA. A final elongation of 1 cycle long was carried 
out at 72°C for 20 minutes. The reaction was held at 4°C, overnight. All the preparations 
for the amplifications were done on ice and reactions were performed in a Hybaid 
DNASprint PCR apparatus. The non-mutated, template DNA was removed by digestion 
with Dpn I, for 2hrs at 37 °C. A 10 µl aliquot of the reaction was analysed by the 
addition of 1 µl of 6 X loading dye and separation of products on 0.8 % agarose gels. 
 
2.2.1.6 DNA purification from agarose gels 
DNA was excised from 0.8 % (w/v) agarose gels using sterile scalpel blades and was 
purified according to the Wizard® SV gel and PCR Clean-Up System (Promega) 
according to manufacturer’s instructions.  
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2.2.1.7 DNA purification from PAGE 
The desired DNA fragment was eluted in 60 µl TE (1 mM EDTA, 10 mM Trizma) at 4 
˚C, overnight. 
 
2.2.1.8 DNA Ligation 
For ligations, 10:1 pmole insert to vector ratio, 2 units of T4 DNA ligase (Promega) and 
1 X ligation buffer (Promega) in a final volume of water up to 20 µl was used. The 
ligation reaction was incubated at 22°C overnight and 10 µl of the reaction was used for 
transformation.  
 
2.2.1.9 Production of competent Escherichia coli (E. coli) 
The rubidium chloride method of making competent cells was used. E.coli, JM109 or 
DH5α were grown overnight in 5 ml Luria Broth (LB) (Appendix II). This was used as a 
starter culture to inoculate 100 ml LB. When an OD530 of approximately 0.35 was 
reached, the culture was poured into 2 x SS34 tubes and was placed on ice for 15 
minutes. The cells were pelleted in a Beckman J2-21centrifuge at 4 000 x g for 5 
minutes. The supernatant was poured off and the cells were resuspended in 10.5 ml ice-
cold TFB-I (100mM RbCl, 50 mM MnCl2, 30 mM potassium acetate, 10 mM CaCl2, 15 
% glycerol) per tube. The contents of each tube were pooled and incubated on ice for 90 
minutes. Cells were centrifuged for 5 minutes under the same conditions as described 
earlier. The pelleted cells were resuspended in 3.5 ml TFB-II (10 mM MOPS pH 7.0, 10 
mM RbCl, 75 mM CaCl2, 15 % glycerol). The cell solution was divided into 100 µl 
aliquots and flash frozen in liquid nitrogen. The competent cells were stored at -70°C.  
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2.2.1.10 Transformation of DNA 
Competent cells were removed from -70°C and thawed on ice for 5 minutes. The cells 
were transferred to sterile polypropylene tubes and plasmid DNA was added to the tubes 
and left on ice for 20 minutes. The cells were then subjected to heat shock at 42°C for 45 
seconds and placed on ice for 2 minutes. The cells were incubated for an hour at 37°C 
with shaking, after the addition of 900 µl LB. The cells were centrifuged for 2 minutes at 
11 000 x g. After removal of 900 µl of the supernatant, the cells were resuspended in 100 
µl LB. The cells were plated out on Luria Agar (LA, Appendix II) plates containing 100 
µg/ml Ampicillin. The plates were incubated at 37°C overnight. 
 
2.2.1.11 DNA extraction from E. coli 
2.2.1.11.1 Phenol-based quick small scale plasmid preparation 
Bacterial colonies were picked and grown, shaking overnight at 37°C in 5 ml LB 
supplemented with 100 µg/ml ampicillin. A 1.5 ml aliquot was centrifuged at 11 000 x g 
for 2 minutes and the pellet was resuspended in 50 µl 1 X TE, pH 8. To the resuspended 
mixture, 100 µl of TE-buffered phenol and 100 µl of a mixture of isoamyl 
alcohol/chloroform (24:1) was added. The cells were shaken for 3 minutes at room 
temperature, and centrifuged at 11 000 x g for 3 minutes. The aqueous phase ~50 µl was 
removed and the DNA was precipitated for 30 minutes at -70°C, by the addition of 18 µl 
of 7.5 M Na Acetate and 140 µl of cold absolute ethanol. The precipitated DNA was 
centrifuged at 11 000 x g for 10 minutes. The pellets were washed with 70 % ethanol and 
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2.2.1.11.2 Large-scale plasmid preparation 
Large-scale plasmid preparations were performed using the protocol supplied by the 
manufacturer Qiagen (GmbH, Germany). The large-scale plasmid isolation procedure 
was used to make stocks of the DNA. The DNA, precipitated by ethanol, was air-dried 
for 5 minutes and was resuspended in appropriate volumes of sterile nuclease-free water 
(Promega) and stored at 4°C or -20°C.  
 
2.2.1.12 DNA quantification 
For large scale plasmid preparations, DNA was diluted 1:100 and the concentration was 
determined using the absorbance measured at 260 and 280 nm. For the quantification of 
digested and purified DNA, 1 µl of the DNA sample was loaded onto an agarose gel and 
the quantity of the DNA was estimated by comparing it to the 500 bp band (representing 
150 ng/5 µl loaded) of the 100 bp DNA ladder (Promega). 
 
2.2.1.13 DNA sequencing  
All the PCR products were sequenced for verification of correct sequence in the 
assembly of constructs, or for the introduction of the relevant mutations during site-
directed mutagenesis. Constructs were sequenced in both directions by the DNA 
Sequencing Service, in the Department of Molecular and Cell Biology, University of 
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2.2.2 Cell Culture 
2.2.2.1 Maintenance of cell cultures 
All the tissue culture cells were grown and maintained in a humidified incubator in 5 % 
CO2 at 37°C. Mouse fibroblasts and CHO A7 cell were maintained in complete growth 
medium [Dulbecco’s modified Eagle’s medium (DMEM)/Ham’s F-12 supplemented 
with 20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (Hepes), pH 7.5, 10 % 
foetal calf serum (FCS) and 10 U/ml Penicillin-10 µg/ml Streptomycin]. All growth 
medium that included FCS, contained FCS that was heat inactivated at 56°C for 30 min. 
The CHO M2 cell line was maintained in DMEM growth medium (supplemented with 
20 mM Hepes, pH 7.5 and 10 % FCS and10 U/ml Penicillin-10 µg/ml Streptomycin).  
Cells were thawed quickly to inoculate a flask that contained 10 ml growth medium 
containing 30 % FCS. The medium was left on overnight and replaced with complete 
growth medium containing 10 % FCS the following day.  
 
Medium was removed after every 2-3 days and was replaced with fresh medium till 
confluent. To split the cells, the medium was removed and 5 ml of trypsin-EDTA [0.5 % 
trypsin in phosphate buffered saline (PBS), Appendix II] was added to the cells, and 
incubated at 37°C for 2-3 minutes. The cells were removed from the flask and transferred 
into a 10 ml tube. The tube was centrifuged for 30 seconds at 2 000 x g. The supernatant 
was discarded and the remaining pellet was resuspended in 2 ml complete medium, and 
was used to inoculate flasks.   
 
To freeze cell cultures, cells were trypsinzed and lifted as for splitting. The cells were 
resuspended in 2 ml 10 % Dimethyl sulfoxide (DMSO) in heat inactivated FCS and left 
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on ice for 20 minutes. Cells were divided into 500 µl aliquots and stored overnight at -
70°C and transferred to liquid nitrogen for storage.  
 
2.2.2.2 Transfections 
All cell lines were transfected with 10-12 µg of plasmid DNA according to the Calcium 
Phosphate, Profection Mammalian Transfection System protocol (Promega). The day 
after transfection, the medium was replaced with 400µg/ml Hygromycin-supplemented 
medium to select for positive colonies, and incubated until separate clones were visible. 
Colonies were picked using sterile swabs dipped in trypsin-EDTA, and seeded into 12 
well plates. Stable clones were assessed for LDLr expression by Western blot. For 
transient transfections cells were transfected with 3 µg DNA in a 6 well plate. The day 
after transfection, cells were harvested and analysed by Western blot or analysed by 
fluorescent microscopy.   
 
2.2.2.3 Fixing of cells 
Cells were grown on cover slips overnight in complete growth medium, supplemented 
with 10 % FCS. Medium was aspirated from the cells. 500 µl of 4 % paraformaldehyde 
(PFA) in,250 mM Hepes, pH 7.5 was added, and incubated at room temperature for 20 
minutes. The PFA was removed and the cells were washed thrice with PBS. The final 
PBS wash was not removed until the cover slips were placed onto slides which had a 
drop of MOWIOL (Aldrich) on it. The slides were left to dry for 30 minutes at room 
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2.2.2.4 Fluorescent microscopy 
Untransfected and GFP-transfected cells were grown on coverslips overnight in complete 
growth medium containing 10 % FCS and either visualized under a fluorescent 
microscope fitted with a GFP filter which measures the excitation wavelength between 
395-440 nm (Zeiss microscope), or fixed and then visualised under the fluorescent 
microscope.  
 
2.2.2.5 Shedding assay 
LDLr expressing cells were plated into 6 well plates in complete growth medium 
containing 10 % FCS, to grow to 90 % confluency overnight. Cells were washed with 
PBS and medium was replaced with 1 ml Optimem (Gibco BRL Life Technologies, Inc) 
in the presence or absence of 1 µM phorbol 12,13-dibutyrate  (PDBu) and / or 10 µM 
TAPI (Peptides International). Medium and cells were collected after 4 hours.  
 
2.2.2.6 Harvesting of Cells 
The medium was removed and centrifuged for 10 minutes at 11 000 x g to pellet any 
floating cells. The cells were scraped off on ice, in 1 ml PBS. A second ml of PBS was 
added to the cells in order to scrape off the remainder. The tubes were centrifuged on a 
bench top microcentrifuge at 11 000 x g for 2 minutes. The supernatant was discarded 
and the pellet was resuspended in 100 µl Triton Lysis Buffer [1 % Triton X-100, 50 mM 
Hepes pH 7.5, 0.5 M NaCl, 1 mM phenylmethylsulphonyl fluoride (PMSF)]. This was 
incubated on ice for 20 minutes after which the tubes were centrifuged for 10 minutes at 
11000 x g. The harvested cells were either used immediately or stored at -20°C until 
needed.  Medium samples were either concentrated 10-fold immediately; using Microcon 
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Ultracel® YM-30 centrifuge tubes (Millipore), or stored at -20°C and concentrated 
prior to loading on sodium dodecyl sulphate (SDS)-PAGE.  
 
2.2.3 Protein Analysis 
2.2.3.1 Protein quantification 
The Bradford method was used to determine protein concentration (Bradford, 1976). 
Protein samples were diluted up to 800 µl in water and 200 µl of Bradford reagent (Bio-
Rad) was added, mixed and incubated for 5 min at 22°C. The reaction was zeroed against 
a blank sample and read at 595 nm. Protein samples were quantified using the slope of an 
IgG or albumin standard curve, where applicable.  
 
2.2.3.2 SDS-PAGE gels 
SDS-PAGE gels were cast and run in a Bio-Rad PROTEAN II gel apparatus (Laemmli, 
1970). Protein samples (20 µl) were prepared by adding 5 µl 5 X SDS sample buffer 
(62.5 mM Tris-HCl pH 6.8, 2 % SDS, 10 % glycerol, 0.001 % Bromophenol Blue) for 
non-reducing conditions. For shedding experiments, equal amounts of cell lysate (~40 
µg) and an equal volume of medium was used. When required, protein samples were 
reduced with 5 X SDS sample buffer containing 5 % β-mercaptoethanol (β-ME), and 
boiled for 5 min.  
Protein samples were separated on SDS PAGE (7 % gel), containing running gel buffer 
(0.375 M Tris pH 8.8, 0.1 % SDS), 0.1 % AMPS and 7 µl TEMED made up to 10 ml 
with water. The 3 % stacking gel was made up of stacking gel buffer (0.125 M Tris pH 
6.8, 0.1 % SDS), 0.3 % AMPS and 20 µl TEMED. The gels were run in 1 X Running 
Buffer (0.025 M Tris pH 8.3, 0.192 M Glycine, 0.1 % SDS) at 50 mAmp. 5 µl Prestained 
marker (Bio-Rad) was used. 
  48 
2.2.3.3 Gradient gels 
A gradient mixer that had 20 % acrylamide gel solution in the right chamber and 5 % 
acrylamide gel solution in the left chamber was used to mix and pour a 5-20 % gel in a 
gel casting apparatus. After the resolving gel was set, the stacking gel was poured and the 
combs were placed for well formation. For the non-denaturing PAGE, SDS was not 
added to protein samples and gel buffers.  
 
2.2.3.4 Coomassie Staining of SDS gels 
SDS gels were stained for a minimum of 45 minutes to 16 hours in Coomassie staining 
solution [50 % (v/v) methanol, 10 % (v/v) acetic acid, 0.25 % (w/v) Coomassie brilliant 
blue] and destained in destaining solution [25 % (v/v ) ethanol, 10 % (v/v) acetic acid] 
until bands became prominent and the background became clear. 
 
2.2.3.5 Western Blotting 
The gels were soaked in blotting buffer (25 mM Tris pH 8.2, 200 mM Glycine, 20 % 
(v/v) methanol) for 10 minutes and assembled in the blotting apparatus (Bio-Rad) with 
the gel and the nitrocellulose membrane (Hybond-C, Amersham Biosciences) being 
placed into a cassette. The proteins were transferred for an hour at 100 volts, in a cooled 
system.  
 
2.2.3.5.1 Probing nitrocellulose membranes with antibodies 
2.2.3.5.1.1 Probing nitrocellulose membranes with LDLr antibodies 
With the membrane facing protein side up, the membrane was blocked overnight in a 5 
% (w/v) skimmed milk in Tris-buffered Saline-Tween (TBS-T) (0.05 M Tris pH 7.4, 0.2 
M NaCl, 0.1 % Tween-20). The membrane was rinsed thrice with TBS-T. The membrane 
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was incubated with primary antibody at a dilution of 1:500 in 5 % (w/v) skimmed milk in 
TBS-T, to bind for an hour, shaking at room temperature. The antibody solution was 
decanted and washed with TBS-T, once for 15 minutes and thrice for 5 minutes. A 
1:1000 dilution of secondary anti-rabbit/anti-goat antibody conjugated to horse radish 
peroxidase (HRP) (Amersham Biosciences, Sweden) in 5 % (w/v) skimmed milk in 
TBS-T was incubated for an hour, shaking at room temperature. The membrane was 
washed as before and detected in the dark room using equal amounts of detection 
reagents 1 and 2 (ECL Plus™ Western Blotting Detection kit, Amersham Biosciences, 
Sweden). This solution was left on for 1 minute and placed in cling wrap with the protein 
side up, exposed in the dark, to X-ray Hyperfilm™ ECL photographic film (Amersham 
Biosciences, Sweden) for the required time. The X-ray film was developed by placing 
the film in developer for 1 minute and rinsing in water. The film was then placed into 
fixer for a minute after which it was rinsed in water and left to dry. 
 
2.2.3.5.1.2 Probing nitrocellulose membranes with ADAM antibodies 
The same procedure was followed as for the LDLr antibodies, except for the following 
changes: For the primary antibody incubation of TACE, ADAM 9 and ADAM 10 
antibodies, overnight incubation at 4°C was performed. Antibody dilution of 1:500 was 
used for TACE and, 1:1000 were used for ADAM 9 and 10, respectively. The dilutions 
of primary antibodies were made in 2.5 % (w/v) skimmed milk in TBS-T. The secondary 
antibodies were incubated in 5 % (w/v) skimmed milk in TBS-T for an hour, shaking at 
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2.2.3.6 Densitometry 
Blots were scanned using GeneSnap (Vacutec) and analysed with GeneTools software to 
quantify protein bands. 
  
2.2.3.7 Cross-linking of intact cells 
Cells were plated out into 6 well plates and grown overnight. Medium was removed from 
cells and cells were washed 3 times with 1 ml PBS (pH 8.0). A final concentration of 1 
mM Bis Sulfosuccinimidyl suberate (BS3) (Pierce Biotechnology) was added and 
incubated at 4°C for 30 minutes. A quenching solution (10 mM Tris) was added for 15 
minutes at 22°C. Cells were harvested as described before.  
 
2.2.3.8 Continuous fluorogenic peptide assays 
1 µM TNF-α stalk substrate, 1.2 ml 2 X buffer (100 mM Tris-Cl pH7.4, 50 mM NaCl, 8 
% glycerol) and water to a final volume of 2.5 ml was combined. Cell lysate (100 µg) 
was added after 5 minutes once a stable fluorescent reading was obtained. The stirred 
reaction was incubated at 37°C and fluorescence was measured continuously at an 
excitation wavelength of 320 nm and emission wavelength of 420 nm on the Cary 
Eclipse (Varian) fluorimeter for 90 minutes.  
 
2.2.4 Plasma studies 
2.2.4.1 Collection of plasma 
Informed consent was obtained from individuals who donated blood. Fasting blood was 
collected in EDTA tubes and centrifuged immediately for 15 minutes at 5 000 x g at 4°C. 
Plasma was carefully removed. Plasma samples were pooled and final concentrations of 
1 mM PMSF, 1 mM Hepes, pH 7.4 and 5mM CaCl2 were added to plasma. A 1:100 
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dilution of a cocktail mix of protease inhibitors (Calbiochem) was also added. Plasma 
samples were either used immediately or stored at -70°C.  
 
2.2.4.2 Lectin Affinity purification 
200 µl of lentil lectin Sepharose beads (Amersham Biosciences, Sweden) were washed 5 
times with 1ml wash buffer/binding buffer [20 mM Tris-Cl pH 7.4, 0.5 NaCl] by 
centrifugation for 30 seconds at 11 000 x g, and removing the supernatant. An equal 
volume of binding buffer was added to the plasma sample, and 1ml of this was incubated 
for half an hour at a time. The incubation and washing steps were carried out on ice, with 
constant shaking. The lentil lectin Sepharose beads were washed 5 times with 1ml wash 
buffer, shaking on ice. The proteins were eluted with 100 µl 0.2 or 0.5 M α-D-
mannopyranoside. The buffer was exchanged with water and the protein samples were 
concentrated using microcon (Millipore) centrifuge tubes. 
 
2.2.4.3 Immunoprecipitation (IP) 
Plasma samples were immunoprecipitated according to the ExactaCruz (SantaCruz 
Biotechnology, Inc.) protocol. Briefly, the protocol entails making an IP-matrix complex 
for sample incubation. Plasma samples (1 ml) were pre-cleared with 45 µl 50 % protein 
G slurry, for 2 hours rotating at 4°C. The IP antibody-IP matrix complex was made using 
50 µl of IP matrix and incubating it with 2.5 µg C7 anti-LDLr (Research Diagnostics, 
Inc.) for 2 hours rotating at 4°C. The pelleted IP antibody-IP matrix was washed twice 
with PBS and 1 ml of pre-cleared plasma sample was added and rotated overnight at 4°C. 
The precipitate was washed 3 times with PBS, and 40 µl 2 X sample buffer was added 
and boiled for 5 minutes, prior to loading onto SDS-PAGE (7 % gel). 
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2.2.4.4 Removal of high abundance proteins from plasma using ProteoMiner protein 
enrichment kit (Bio-Rad) (Guerrier et al., 2006) 
The ProteoMiner protein enrichment (Bio-Rad) protocol was followed. Briefly, the 
column was prepared by washing with wash buffer. Plasma (1 ml) was added to the 
column and incubated at room temperature, rotating for 2 hours. After removal of plasma 
by centrifugation, the column was washed 3 times with 1 ml of wash buffer. Before 
elution, the column was washed with 1 ml of water. To elute proteins, 100 µl of elution 
buffer was added to column and incubated rotating at room temperature for 15 minutes. 
After incubation the column was centrifuged into a new tube. This step was repeated 
twice and the eluant was pooled. To confirm successful enrichment, fractions were 
analysed on SDS-PAGE (7 % gel) and stained by Coomassie. 
 
2.2.4.5 One-Step Western 
To reduce non-specific binding of the secondary antibody for some of the plasma 
experiments, the One-Step Western (GenScript) method was used.  A mixture-1 was 
prepared using 12.5 µl (~1.25 µg) of polyclonal anti-LDLr with 50 µl WB-1, and 
incubated for 40 minutes at room temperature. Pretreat A was mixed with Pretreat B. The 
membrane was incubated in 5 ml of the Pretreat mixture for 5 minutes, on a shaker. The 
membrane was rinsed twice in 5 ml 1 X wash solution. Mixture-1 was mixed into 5 ml of 
WB solution. The membrane was incubated in this mixture for 40 minutes on a shaker, at 
room temperature. The membrane was rinsed in 1 X wash solution, and then washed with 
5ml of wash solution, thrice for 10 minutes, on a shaker. For detection, the membrane 
was incubated for 1 minute with the LumiSensorTM Chemiluminescent HRP Substrate 
provided in the kit. The membrane was exposed to X-ray film accordingly. The X-ray 
film was developed by placing the film in developer for 1 minute and rinsing in water. 
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The film was then placed into fixer for a minute after which it was rinsed in water and 
left to dry. 
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Chapter 3: 




This chapter discusses the sub cloning and site-directed mutagenesis of the LDLr. 
pLDLr2 encodes the wild-type human LDL receptor (Yamamoto et al., 1984). For 
mammalian expression, the LDLr sequence was sub cloned into the expression vector 
pcDNA3.1 (H)-. This vector was chosen since it had compatible restriction enzyme sites 
as well as for the Hygromycin selection marker that the vector provided for transfected 
cells, as the mouse fibroblasts used in this project were resistant to Neomycin, a common 
antibiotic marker found on other mammalian expression vectors. 
 
3.1.1 Construction of the LDLr expression vector 
The sub cloning strategy involved the removal of the LDLr insert from pBR322 by Xba I 
and Sma I [Fig.3.1 (a).]. The vector pcDNA3.1 (H)-, was digested with Xba I and EcoR 
V to create compatible sites for ligation [Fig.3.1 (b).]. Both Sma I and EcoR V are blunt 
end cutters and therefore the blunt ends could re-ligate. Upon re-ligation, though, the 
restriction enzyme site was lost and the presence of the insert was confirmed by digestion 
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3.1.2 Site-directed mutagenesis of the LDLr 
The LDLr was mutated to either the 792-LDLr or the JD-LDLr (Fig 3.2). These 
mutations occur in some patients presenting with FH and they have been shown in a 
previous study to be of interest since they are shed more efficiently than the wild-type 
counterpart (Begg et al., 2004). Both receptors are internalisation defective in that the 
pLDLr 2  
8.37 kbp 
Xba I  
Sma I  




0 / 8369 bp 
pc-wtLDLr  
8.4 kbp 
Xba I  
Hind III  
Bgl II  





















Figure 3.1: A flow diagram depicting the sub cloning pc-wt-LDLr. 
The LDLr insert was digested from the original vector with Xba I and Sma I (a) 
and sub cloned into pcDNA3.1(H)- (b) to give a final construct called pc-wt-LDLr 
(c).  
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792 construct has a premature stop codon at position 792, resulting in a truncated 
receptor with a shortened cytoplasmic tail (Lehrman et al., 1985; Davis et al., 1986), 
while the JD construct is a full length construct with a tyrosine to cysteine substitution at 




The site-directed mutagenesis was adapted from the Stratagene Quickchange method. 
For the 792-LDLr construct, the primer contained a silent mutation that created an Aat II 
site (Appendix I, Fig. II.). For the JD-LDLr construct, the primer contained a silent 
mutation that created a Bfi I site (Appendix I, Fig. II.). The restriction enzyme site was 
introduced so that clones could be screened for the presence of the mutation. After the 
mutagenesis reaction, the PCR product was digested with Dpn I. The reaction was 
792 807 
                                                                    WT TM O EGF LB Trp 
807 
                                                                    JD TM O EGF LB Cys 
792 
                                                                     792 TM O EGF LB Stop 
Tyr 
Key: 
WT: wild-type LDLr 
792: 792-LDLr 
JD: JD-LDLr 
LB: Ligand binding domain 
EGF: EGF homology domain  
O: O-glycosylated domain 
TM: Transmembrane domain 
 
Figure 3.2: Schematic representation of the LDLr constructs (adapted from 
Begg et al., 2004). 
The wt-LDLr was mutated to either the 792-LDLr, containing a stop codon at position 
792, or the JD-LDLr, containing a cysteine (Cys) residue in place of tyrosine (Tyr) at 
position 807.  
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transformed into competent E.coli JM109 cells. Bacterial colonies were picked and 
screened for the presence of the mutation by restriction enzyme digestion. The DNA was 




3.2.1 Sub cloning of the LDLr into pcDNA3.1(H)- 
The LDLr was sub cloned from pLDLR2 (Yamamoto et al., 1984; Begg et al., 2004). 
The LDLr sequence was digested and ligated into pcDNA3.1(H)-. The ligation reaction 
was transformed into competent E.coli JM109 cells. Ampicillin resistant clones were 
analysed by small scale plasmid preparation and restriction enzyme digests. The 
identified positive clones were grown and the plasmid DNA was extracted. The DNA 
was restriction enzyme digested to confirm the correct sequence.  
 














Xba I  
Hind III  
Bgl II  





Figure 3.3: Confirmation of pc-wtLDLr by restriction enzyme digest. 
Lane 1: λ DNA digested with EcoR I and Hind III. Lane 2: undigested pc-wt-LDLr. Lane 
3: DNA digested with Xba I and Hind III. Lane 4: DNA digested with Bgl II. Lane 5: 
DNA linearised with Nhe I. 
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In Figure 3.3, lane 2, undigested DNA was loaded as a control. Lane 3 depicted the 
presence of the 2.8 kbp LDLr insert and the 5.6 kbp pcDNA3.1 (H)- vector. Lane 4 
showed the product of a digest with Bgl II, which resulted in a 2.7 kbp fragment as well 
as a 5.7 kbp fragment as a Bgl II site occured once in the LDLr insert and once in the 
vector. Lane 5 showed a Nhe I digest, resulting in an 8.4 kbp linearised plasmid. 
 
3.2.2 Site-directed mutagenesis of the LDLr 
Site-directed mutagenesis was used to convert wt-LDLr template into a 792-LDLr or JD-
LDLr construct. The PCR product was Dpn I digested and transformed into E.coli. 
Ampicillin resistant colonies were subjected to small scale plasmid preparation and these 
were screened with relevant enzymes for the introduction of silent mutations. The 
positive clones were sequenced to confirm the introduction of relevant mutations.  











Xba I  Hind III  












Bgl II  
Figure 3.4: Confirmation of pc792-LDLr by restriction enzyme digest. 
Lane 1: λ DNA digested with EcoR I and Hind III. Lane 2: undigested pc792-LDLr. 
Lane 3: DNA digested with Aat II. Lane 4: DNA digested with Bgl II. Lane 5: DNA 
digested with Xba I and Hind III.  
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Restriction enzyme digests of the pc792-LDLr were shown in Figure 3.4. In lane 5 a 
digest with Xba I and Hind III was seen. These two enzymes were used to confirm the 
presence of the LDLr insert. The digest released the 792-LDLr insert (2.8 kbp) from the 
vector (5.6 kbp). In lane 4, the digest with Bgl II indicated the formation of two bands, a 
2.7 kbp fragment as well as a 5.7 kbp fragment. Bgl II cuts once in the LDLr insert and 
once in the vector. The Aat II digest (lane 3) showed bands of 3.45, 2.5, and 1.7 kbp and 
smaller bands that could not be detected since they were too small. The digest showed 
that the mutation had been incorporated, since in the absence of the mutation the 
expected band sizes were 3.45 and 4.27 kbp, while in the presence of the mutation the 
4.27 kbp band was split into the 2.5 and 1.7 kbp bands, due to the additional Aat II site.  
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pcJD-LDLr 
8.4 kbp  
Xba I  Hind III  












Eco RV  
Eco RV  
Bgl 
II  
Figure 3.5: Confirmation of pcJD-LDLr by restriction enzyme digest. 
Lane 1: λ DNA digested with EcoR I and Hind III. Lane 2: undigested pcJD-LDLr. 
Lane 3: DNA digested with Bgl II. Lane 4: DNA digested with Nhe I and Eco RV. 
Lane 5: DNA digested with Bfi I. Lane 6: pc-wt-LDLr digested with Bfi I. 
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Figure 3.5 showed the restriction digest of pcJD-LDLr. Lane 2 showed the undigested 
forms of the DNA. Lane 3 was digested with Bgl II, which released a 2.7 kbp band and a 
5.7 kbp band. The digest with Nhe I and Eco RV displayed bands of 6.5, 1.1 and 0.8 kbp 
sizes (lane 4). In lane 5 the DNA was digested with Bfi I, and bands of 2.7, 2.0, 1.4, 1.2 
and 0.6 kbp as well as a band of 4.1 kbp band was seen. The 4.1 kbp band (in lanes 5 and 
6) was due to the partial digest as that band was digested further into the 2.7 and 1.4 kbp 
bands. Lane 6 had pc-wt-LDLr digested with Bfi I as a control, to compare to the mutated 
construct in lane 5, where the appearance of the 1.2 kbp band was seen. There were two 
1.4 kbp bands, and the one 1.4 kbp band was split into a 1.2 kbp and 200 bp band if the 
mutation was present, as seen in lane 5.  
 




The LDLr was subcloned successfully from pLDLr2 into pcDNA3.1 (H)-, as the 
restriction enzyme digest confirmed the presence of the insert. Additional digests showed 
bands of expected base pair sizes.  
 
The constructs that were made by site-directed mutagenesis, were analysed by restriction 
enzyme digests and showed correct banding patterns. In addition, nucleotide sequencing 
confirmed the presence of desired mutations. All constructs gave bands of calculated size 
and no additional mutations were introduced during mutagenesis reactions.     
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Chapter 4: 




In order to study LDLr ectodomain release, the receptor was tagged with the GFP to 
detect LDLr expression and assay ectodomain release. The GFP has been proven to be a 
useful tool in the visualisation of protein expression, trafficking and interactions between 
other proteins by means of fluorescent microscopy (Kaether and Gerdes, 1995; Ogawa et 
al., 1995), fluorescence-activated cell sorting (FACS) (Zeyda et al., 1999), or fluorescent 
resonance energy transfer (FRET) (Pollok and Heim, 1999). The construct used in this 
project was a GFP sequence that was codon optimised for human expression, called 
humanised Renilla reniformis (R. reniformis) or hrGFP, as it was isolated from the 
anthazoan R. reniformis. The hrGFP is less toxic than the Aequorea victoria GFP 
counterpart, allowing for the establishment of stable cell lines expressing GFP (Kirsch et 
al., 2003). 
 
The C7 monoclonal antibody to the LDLr binds cellular LDLr in binding studies (Russel 
et al., 1989) and binds to cell lysate of LDLr expressing cells in a Western blot, under 
non-reducing conditions (data not shown). The LDLr is a cystein-rich protein and 
therefore the C7 monoclonal antibody, which is directed to the ligand binding domain, 
does not recognise the reduced form of the receptor. In addition, the C7 antibody does 
not recognise the non-reduced soluble LDLr from medium by standard Western blotting 
conditions. The soluble LDLr was previously detected by [35S] methionine labelling of 
cells combined with the IP with the C7 antibody and autoradiography (Begg et al., 2004). 
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Soluble LDLr from medium also bound a C7 antibody column. The C7 antibody seemed 
to recognise the soluble LDLr during IP, but not in a Western blot after it had been 
transferred to nitrocellulose. The current theory is that the epitope on the soluble LDLr to 
the C7 antibody might be masked after transfer. This approach was not used since it 
required lots of optimisation and it would not have been feasible to assess stable clones 
expressing LDLr in this way.  
 
 
The rationale for making a GFP-LDLr fusion protein in this project was that expressing 
clones transfected with tagged constructs could be visualized easily by fluorescent 
microscopy. In addition, intracellularly-tagged GFP proteins could be visualised through 
the secretory pathway (Kaether and Gerdes, 1995) and the GFP-tagged proteins that were 
secreted into the medium could be assessed by fluorimetry (Wacker et al., 1997). In the 
case of the LDLr, since it is a membrane protein and subsequently shed, the receptor had 
to be tagged on the extracellular N-terminus so that soluble LDLr released into the 
medium could be measured by fluorimetry in a similar way as the approach used for 
secreted constructs (Wacker et al., 1997). 
 
The first part of this chapter describes the construction of two GFP vectors, both 
containing signal peptide (SP) sequence at the start of GFP sequence. The second part 
focuses on the expression of these constructs in mammalian cells.  
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The one GFP vector [named pcGFP(s)] has a stop condon at the end of GFP sequence 
[Fig. 4.1 (a)], to serve as a control for downstream experiments, while the second GFP 
vector [named pcGFP(MCS), Fig. 4.1 (b)] has an open reading frame for the introduction 









Xba I Kpn I Hind III 
GFP LDLr 
 
Xba I Hind III 
pcGFP(s) 





Represents restriction enzyme sites (namely; Bam HI, Kpn I, Cla I and Not I) at the end of GFP 
sequence  
Represents signal peptide sequence at the start of GFP sequence 
 
Represents GFP sequence 
Represents pcDNA 3.1(H)- sequence 
Figure 4.1: A schematic representation of the vector constructs.  
(a). pcGFP(s) cloned via Xba I and Hind III into pcDNA 3.1(H)-. This was used as a 
control in subsequent experiments. (b). pcGFP(MCS) was cloned via Xba I and Hind III. 
(c). The LDLr was cloned into pcGFP(MCS) via Kpn I and Hind III. This is the 
experimental vector. 
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The approach used in the construction of GFP vectors included PCR and cloning. For the 
construction of GFP, the overlap PCR method was used so that the SP of the LDLr could 
be incorporated into the start of the GFP sequence. This method entails a two step 
approach: firstly the SP is amplified and the GFP sequence is amplified separately [Fig. 
4.2 (i)], followed by a final PCR step that incorporates the SP and GFP sequence [Fig. 
4.2 (ii)]. 
 
(ii) PCR of sp-GFP(s) 
(i) PCR of GFP(s) 
5’ 3’ 
3’ 








Forward and reverse primer for SP  
Forward and reverse primer for GFP(s)  
Figure 4.2: Overlap PCR for the construction of sp-GFP(s). 
(i). The SP and GFP were amplified and purified. (ii). The PCR products acted as a template 
for the next PCR, using the two flanking primers, to fuse the two products. The sp-
GFP(MCS) was constructed in the same way. 
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The GFP amplification products were digested, cloned and sequenced in pBS-K [Fig. 4.3 
(a).]. When sequencing was confirmed the insert was sub cloned into pcDNA3.1(H)- 










Xba I  Hind III  















Bgl II  
 
(b).  
Figure 4.3: A flow diagram depicting the cloning procedure of pc-GFP(s). 
The sp-GFP(s) insert was digested from the sequencing vector (a) and sub cloned into 
pcDNA3.1(H)- (b) to give a final construct (c) called pcGFP(s). The pcGFP(MCS) 
vector was constructed in the same way. 
 




For the construction of GFP-LDLr, the LDLr was amplified by PCR, digested, gel 
purified and cloned into pBS-K vector for sequencing and subsequent cloning [Fig. 4.4 
(i-ii)]. Due to the large size of the LDLr, it had to be digested into 3 fragments and 
(ii) Digest & clone 
into pBS-K 




Kpn I  Hind III  
Kpn I 
pcGFP(MCS) 
6.4 kbp  
Xba I  
Bgl II  
Hind III  
pcGFP-wtLDLr 
9.2 kbp  
Xba I  Hind III  
Bgl II  
Kpn I  







(i) PCR of LDLr 
SP 
LDLr  
Figure 4.4: A flow diagram depicting the construction of pcGFP-wt-LDLr. 
(i). The LDLr was amplified. (ii). The PCR product was digested and cloned into pBS-K 
for sequencing. (iii). On confirmation of the correct sequence, the LDLr was cloned into 
pcGFP(MCS), via Kpn I and Hind III. 
 
  67 
cloned into pBS-K, for sequencing. Upon confirmation of correct sequence, the LDLr 




4.2.1 Cloning of the GFP constructs 
Since the LDLr is a transmembrane protein and expressed at the cell surface, it contains a 
SP sequence at the 5’ end (Yamamoto et al., 1984). In the construction of the GFP 
vectors a SP needed to be incorporated at the 5’ end for the correct processing of the 
translated GFP and GFP fusion protein. The overlap PCR method was used to create a 
fusion of SP and GFP sequences. The reverse primer of the SP contained GFP sequence 
at the 3’ end. The LDLr sequence which was in pcDNA3.1(H)- was used as template 
DNA for the amplification of the SP and LDLr sequence. GFP sequence was amplified 
from the phrGFP vector. Two GFP constructs were made, one containing a stop codon at 
the end of the GFP sequence [Fig. 4.1 (a).], as a control for further experiments, and a 
second GFP construct containing an open reading frame and restriction enzyme sequence 
coding for a multiple cloning site (MCS) [Fig. 4.1 (b).]. The GFP construct containing 
the stop codon was termed GFP(s), while the GFP containing an open reading frame was 
termed GFP(MCS). 
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In Fig. 4.5 (a), the SP DNA sequence was amplified with a reverse primer that resulted in 
a SP construct that had GFP sequence at the 3’ end. The products were separated on a 12 
% polyacrylamide gel. There were no products of 80 bp seen in the controls (lanes 2-4). 
The 80 bp signal peptide PCR product (lane 5), was excised from the gel and the DNA 
was resuspended in TE overnight.  
 
The GFP(s) was amplified with a forward primer that included SP sequence, and a 
reverse primer that included a stop codon at the end of the 720 bp GFP sequence [Fig. 
4.5 (b).]. The PCR controls were shown in lanes 3-5 in Fig. 4.5 (b), and showed 
nonspecific amplification of template DNA as seen at the top of the lanes. The 720 bp 
product [Fig. 4.5 (b), lane 5] was excised from the gel and the DNA was gel purified. For 
the generation of the sp-GFP construct the template for the PCR, consisted of TE-
resuspended SP and the purified GFP(s) product and the primers used here were the 
forward primer of the SP and the reverse primer of GFP in order to obtain what is called 
‘a zipper reaction’ which resulted in a combined DNA sequence of 800 bp [see Fig. 4.2 
(ii)]. The product of this reaction was seen in Fig. 4.5 (c) lane 5, in addition to some 

















1   2   3   4      5    
(b). PCR of GFP(s) 












(c). PCR of sp-GFP(s) 
Figure 4.5: Construction of sp-GFP(s). 
Lane 1: DNA ladder markers. Lane 2: no DNA, control. Lane 3: PCR with forward primer 
only. Lane 4: PCR with reverse primer only. Lane 5: PCR with both primers in PCR. 
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minor nonspecific amplification that resulted in truncated products. The desired band was 
excised from the gel, the DNA was purified and digested with compatible enzymes. 
 
The digested DNA was ligated into digested pBS-K overnight. The ligation reaction was 
transformed into competent E.coli cells. Transformed colonies were selected by 
resistance to Ampicillin, as the vector has an Ampicillin resistance gene. Colonies were 
screened for positive clones by small scale plasmid isolation and restriction enzyme 
digestion. The positive clones were identified and DNA was isolated by plasmid 
preparation. The DNA was sequenced to confirm correct GFP sequence and to ensure 
that no mutations were introduced.  
 
The GFP(s) was then sub cloned into pcDNA3.1(H)-. A restriction digest with Xba I and 
Hind III confirmed the presence of the 800 bp insert (Fig. 4.6, lane 3). In lane 4 the DNA 
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 1    2    3    4   5 
Figure 4.6: Confirmation of pcGFP(s) by restriction enzyme digest. 
Lane 1: λ. (EcoR I/Hind III) marker. Lane 2: undigested pcGFP(s). Lane 3: 
pcGFP(s) digested with Xba I and Hind III. Lane 4: pcDNA-GFP(s) digested with 
Xba I and Bam HI. Lane 5: pcGFP(s), linearised with Bgl II.  
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site was removed during the digestion of pcDNA3.1(H)-, and hence a linearised 6.4 kbp 
band was seen. Lane 5 showed DNA digested with Bgl II, which linearised the vector 
outside the MCS. All the bands were of expected size, but the agarose gel was not run 
long enough to see better separation between the linearised 6.4 kbp band of lanes 4 and 5 
and that of the pcDNA3.1(H)- vector band in lane 3.    
 
The sp-GFP(MCS) was constructed in the same way as the sp-GFP(s). The 740 bp sp-
GFP PCR product [Fig. 4.7 (b) lane 5] was purified and amplified together with signal 
peptide DNA [Fig. 4.7 (a) lane 5], to generate a 820 bp product [Fig. 4.7 (c), lane 5].  
 
 
There was some nonspecific amplification of the template DNA, seen in lanes 2-5 of Fig. 
4.7 (b), and there were no products of 80 bp seen in the controls of the amplification of 
the SP [Fig. 4.7 (a), lanes 2-4]. No nonspecific amplification of sp-GFP(MCS) was seen 
in the control lanes 2-4 in Fig. 4.7 (b). The sp-GFP(MCS) [Fig. 4.7 (c), lane 5] product 
was purified, digested and ligated into pBS-K. The ligation reaction was transformed into 
competent E.coli cells. The ampicillin resistant colonies were screened by small scale 
plasmid isolation and restriction enzyme digests to identify positive clones. The DNA 










(a). PCR of signal peptide 






(b). PCR of GFP (MCS) 






(c). PCR of sp-GFP (MCS) 
Figure 4.7: Construction of sp-GFP(MCS). 
Lane 1: DNA ladder markers. Lane 2: no DNA, control. Lane 3: PCR with forward primer 
only. Lane 4: PCR with reverse primer only. Lane 5: PCR with both primers. 
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was sequenced to confirm the sp-GFP(MCS) sequence. The sp-GFP(MCS) was sub 
cloned into pcDNA3.1(H)-.  
 
A restriction digest with Xba I and Hind III confirmed the presence of the 820 bp insert 
(Fig. 4.8, lane 3). In lane 4 DNA was digested with Cla I, as a restriction enzyme site 
occured in the MCS at the end of the GFP sequence. Lane 5 showed DNA digested with 
Bgl II, which linearised the vector outside of the MCS. This vector was used later for the 
introduction of the LDLr sequence. All the digests in Fig. 4.8 had bands of predicted 
size. 
 
The LDLr was amplified from the template, pc-wtLDLr, so that the LDLr construct 
obtained did not contain the SP sequence. Primers that contained restriction enzyme sites 
were used to introduce unique restriction enzyme sites at the 5’ and the 3’ end of the 
pc-GFP(MCS)  
6.4 kbp 
Xba I  Hind III  
Bgl II  

















 1      2       3      4      5   
Figure 4.8: Confirmation of pcGFP(MCS) by restriction enzyme digest. 
Lane 1: λ. (EcoR I/Hind III) marker. Lane 2: undigested pcGFP(MCS). Lane 3: pcGFP(s) 
digested with Xba I and Hind III. Lane 4: pcGFP(MCS) digested with Cla I. Lane 5: 
pcGFP(MCS) linearised with Bgl II. 
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sequence. These allowed for compatible cloning sites for sequencing and subsequent 
ligation into the expression vector.  
 
In Figure 4.9, the LDLr PCR product can be seen as a 2.8 kbp band in lane 5. The 
controls for the PCR do not show any nonspecific amplification of products. The DNA 
was digested with Kpn I and Hind III and cloned into pBS-K for sequencing. The LDLr 
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PCR of the LDLr 
2.8 kbp product 
Figure 4.9: Amplification of the LDLr. 
Lane 1: λ (EcoR I/Hind III) marker. Lane 2: PCR control using no DNA 
template. Lane 3: DNA that has been amplified with forward primer only. 
Lane 4: template DNA that has been amplified with reverse primer only. Lane 
5: Both primers in the PCR. 
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In Figure 4.10, the restriction enzyme digest with Kpn I and Hind III of pcGFP-LDLr 
resulted in a 2.8 kbp LDLr band and a 6.4 kbp pcGFP(MCS) vector band (Fig. 4.10, lane 
3). A digest with Bgl II only (lane 4), revealed a band of 5.5 and 3.4 kbp, since this 
enzyme occurred once in the vector and once in the LDLr sequence. Lane 5 showed a 
digest with Xba I and Kpn I, which resulted in an 8.4 kbp band and the release of the 820 
bp GFP band.  
 
All constructs that were made by PCR, were analysed by nucleotide sequencing and 
restriction enzyme digests were used to determine correct banding pattern. All constructs 
gave correct banding patterns and no unwarranted mutations were introduced during 
PCR. Ultimately, a GFP-LDLr fusion construct was produced as determined by 
restriction enzyme digest and sequencing.     
 











9.2 kbp  
Xba I  Hind III  
Bgl II  
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Figure 4.10: Confirmation of pcGFP-LDLr by restriction enzyme digest. 
Lane 1: λ (EcoR I/Hind III) marker. Lane 2: undigested pcGFP-wt-LDLr. Lane 3: pcGFP-
LDLr digested with Kpn I and Hind III. Lane 4: pcGFP-wt-LDLr digested with Bgl II. 
Lane 5: pcGFP-wt-LDLr digested with Xba I and Kpn I.  
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4.2.2 Expression of the GFP constructs in mammalian cells 
To test the hypothesis that TACE was involved in the shedding of the LDLr, GFP-LDLr 
shedding in TACE activity KO (TACE-/-) mouse fibroblasts was compared to the 
shedding of that in wild-type mouse fibroblasts (TACE+/+). In order to assess the 
cleavage secretion of GFP-LDLr; wild-type and TACE-/- mouse fibroblasts were 
transfected with the GFP and GFP-LDLr constructs. However, these constructs could not 
be stably expressed for a number of reasons, discussed later.   
 
In order to establish whether the constructs were functional; GFP and GFP-LDLr 
constructs were transiently expressed in CHO cells. Expression of the constructs was 
analysed using fluorescent microscopy and Western blotting.  
 
Fluorescence was observed in CHO cells transfected with the phrGFP construct, the 
positive control for the experiment as well as the GFP(s) construct (Fig.4. 11). The cells 




Figure 4.11: GFP expression in CHO cells.  
(a). CHO cells transfected the GFP vector, phrGFP. (b). CHO cells transfected 
with the sp-GFP(s) construct in pcDNA3.1 (H)-, named, pcGFP(s). 24 hours 
after transfection cells were fixed and visualised by fluorescent microscopy 
under 40 x magnification. The cells presented here are representative cells. 
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The sp-GFP(s) construct was expected to be secreted, since it contained a signal peptide 
at the start of the GFP sequence, but does not have a transmembrane domain. The 
fluorescence seen in Figure 4.11 (b) was likely due to newly synthesized GFP that has 
not been secreted from the cell. The GFP-LDLr showed negligible fluorescence (data not 
shown) that was similar to the background fluorescence of the mock transfected cells.  
 
In addition to detection of GFP fluorescence in transfected cells, expression of GFP 
constructs was assessed by Western blotting using GFP and LDLr antibodies. The 
samples were separated under non-reducing conditions, since the polyclonal LDLr 
antibody obtained detected the non-reduced form more effectively than the reduced form 
as the LDLr is a cysteine-rich protein. 
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In the untransfected cells and medium samples that served as controls for the experiment, 
no GFP was detected [Fig. 4.12 (lanes 1 and 2)]. In the GFP transfected cells, GFP was 
detected as a “monomer (~30 kDa), dimer (~60 kDa) (Tsien, 1998) and trimer (90 kDa)” 
in the cell lysate sample (lane 3), indicating that the bands seen here are specific to GFP 
as these bands were not seen in the controls. However, in lane 4 no significant amo unt of 
secreted GFP was detected in the medium. The expression level of GFP-LDLr was less 
than GFP alone, seen as an extremely faint band of ~160 kDa, indicated by the arrow 
[additive of the GFP (~30 kDa) and LDLr size, ~130 kDa, under non-reduced conditions 
(Daniel et al., 1983)] in cell lysate in lane 5. After 4 hours, no GFP-LDLr was detected in 
the medium sample, lane 6. 
Figure 4.12: Western blot showing GFP and GFP-LDLr expression in 
CHO cell lysate and medium samples using the anti-GFP antibody. 
Lane 1: Untransfected cells. Lane 2: medium from untransfected cells. Lane 3: 
pcGFP(s) transfected cells. Lane 4: medium from pcGFP(s) transfected cells. Lane 5: 
Lane: pcGFP-LDLr transfected cells. Lane 6: medium from GFP-LDLr transfected 
cells. To assay for soluble receptors, medium was replaced with serum-free medium 
and harvested after 4 hours. Medium was concentrated 5X and 20 µl was used. ~40 
µg of non-reduced cell lysate samples were separated by SDS-PAGE (10 % gel) 
detected with a GFP antibody by Western blotting. The arrow indicates GFP-LDLr in 
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To complement the data seen in Fig. 4.12, Western blot analysis using a rabbit polyclonal 
antibody to the LDLr was tested against the GFP-LDLr construct. The antibody to the 
LDLr did not detect the presence of the receptor in untransfected cells and medium and 
no nonspecific interaction was obtained [Fig. 4.13 (lanes 1 and 2)]. In lane 3, GFP-LDLr 
transfected cells displayed 3 bands, one that corresponded to the GFP-LDLr construct 
(~160 kDa), another which corresponded to the LDLr as compared to the size (130 kDa) 
of the band seen in the positive control (lane 5) for the experiment, and a low intensity 
component that corresponded to immature GFP-LDLr (~120 kDa). Again, the bands seen 
in lane 3 were not seen in the negative control (lane 1), indicating that the antibody was 

























































Figure 4.13: Western blot showing GFP-LDLr and wt-LDLr expression in 
CHO cell lysate and medium using a rabbit polyclonal anti-LDLr anti-serum. 
Lane 1: Untransfected cells. Lane 2: 5X concentrated medium. Lane 3: pcGFP-LDLr 
transfected cells. Lane 4: 5X concentrated medium from pcGFP-LDLr transfected cells. 
Lane 5: Lane: LDLr transfected cells. Lane 6: 5X concentrated medium from pc-wt-LDLr 
transfected cells harvested after 4 hours. Lane 7: 5X concentrated medium from pc-wt-
LDLr transfected cells harvested after 16 hours. To assay for soluble receptors, medium 
was replaced with serum-free medium and harvested after 4 hours.  Non-reduced samples 
were separated on SDS-PAGE (7 % gel), transferred to nitrocellulose and detected with a 
rabbit polyclonal anti-LDLr. 
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specific to the GFP-LDLr transfected into these cells. No GFP-LDLr was detected in the 
medium, lane 4. Soluble LDLr was detected in both lanes 6 and 7, which were medium 
samples harvested from LDLr expressing cells, after 4 hours and 16 hours, respectively. 
The reason for detecting soluble LDLr in lanes 6 and 7, and not any soluble LDLr of 
GFP-LDLr in lane 4, could be due to higher levels of LDLr expression in lane 5 
compared to GFP-LDLr or LDLr expression in lane 3. 
 
Using the GFP antibody, only one faint band was seen for the GFP-LDLr construct in 
Figure 4.12, lane 5, since it only detected the GFP on the GFP-tagged receptor. The 
LDLr antibody on the other hand seemed to be more sensitive than the GFP antibody 
since it detected 3 bands for the same construct under the same conditions (Fig.4.13, lane 
3). In addition, this indicated that the protein corresponding to the LDLr size did not have 
GFP associated with that construct. Possible origins for these bands are discussed in 
section 4.3. From Figure 4.13, it was evident that the epitope for the LDLr antibody was 
not masked in the GFP-LDLr construct. As with the fluorescent microscopy data, it was 
seen that the expression levels of GFP-LDLr was much lower when compared to GFP or 




Two GFP vectors were made by PCR and cloning. Since the stable expression of GFP 
was unsuccessful in mouse fibroblasts, the expression of GFP and GFP-LDLr vector 
constructs were assessed in CHO cells.  
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Transient expression of GFP in mammalian cells is performed routinely, while the stable 
expression of GFP is more problematic. Producing stable mouse fibroblast cell lines 
expressing GFP(s) or GFP-LDLr were not successful. This could be due to any or a 
combination of the following factors: (i) toxicity of the GFP constructs, (ii) loss of 
expression/overgrowing of non-expressing cells or, (iii) stability of GFP constructs 
(Zeyda et al., 1999). It was also reported that even after cells were sorted by FACS 
analysis so that a 100 percent of cells expressed GFP, a loss of GFP expression was 
observed (Zeyda et al., 1999). Researchers who used the hrGFP construct in Hela cells, 
showed hrGFP expression peaked at 4 days, after which a continual loss in GFP 
expression occurred while the cells were under antibiotic selective pressure (Kirsch et al., 
2003). PCR of non-fluorescent, resistant clones showed the presence of the GFP gene in 
the genome of transfected cells, but Western blots indicated that GFP was not produced 
at the protein level. In addition it was found that for the hrGFP construct, expression 
decreased over time from a population of positive cells, as well as that the GFP linked to 
the cytomegalovirus (CMV) promoter displayed lower fluorescence intensity compared 
to another promoter that emitted a stronger fluorescence signal (Zeng et al., 2003).  
 
Similarly, the author also found that while a percentage of TACE-/- mouse fibroblasts 
were fluorescent (as shown by fluorescent microscopy) a couple of days after 
transfection, none of the selected resistant clones when checked after ~2 weeks, 
expressed GFP (data not shown).  
 
In addition, all PCR products were sequenced and restriction digests of the DNA 
constructs all gave the predicted fragment sizes, validating the integrity of the constructs. 
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To determine if the constructs were transiently expressed in CHO cells, transfected cells 
were analysed by fluorescent microscopy and Western blot.  
 
From the experiments performed (Figures 4.11, 4.12 and 4.13), it could be concluded that 
not only was the GFP-LDLr difficult to express as it seemed to be expressed at low 
levels, it also appeared to be expressed as two proteins. Using the polyclonal antibody to 
the LDLr, it showed that the construct was expressed as two proteins, an LDLr and a 
GFP-LDLr fusion protein. It is also not clear from the Western blot data whether the 
GFP-LDLr was released by ectodomain cleavage, into the medium.  
 
In tobacco plant cells, an ER-targeted GFP-fusion protein was shown to degrade in the 
following manner where the GFP fusion protein was degraded into a smaller protein 
corresponding to GFP alone (Persson et al., 2002). This is a similar trend that the author 
observed in Figure 4.13, lane 3, where the GFP is ‘removed’ or cleaved from the GFP-
LDLr construct. It may be possible that the GFP part of the GFP-LDLr fusion protein 
was not that stable and became cleaved and/or degraded in the ER. 
 
It was possible that proper folding of the GFP-LDLr construct was compromised since a 
30 kDa GFP protein tagged onto the extracellular side of a large receptor might have 
made the overall construct floppy and unstable, not allowing for the proper folding and 
fluorophore formation of GFP, and hence no fluorescence was seen. Researchers have 
tagged GFP to an LDLr before, but this construct was tagged on the intracellular side of 
the receptor, making it a more stable construct (Holst et al., 2001).  
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In this study, the GFP constructs were not investigated further, since a commercial rabbit 
polyclonal antibody to the LDLr could detect soluble LDLr from medium when used in 
Western blots (Fig.4.13, lanes 6 and 7). This method of detecting LDLr ectodomain 
release was preferred and used in further experiments to investigate the role of TACE in 
the ectodomain release of the LDLr. 
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Chapter 5: 




A number of unrelated proteins, including members of the LDLr family undergo 
cleavage near the cell surface to release the ectodomain into the surroundings (Rebeck et 
al., 2006; Edwards et al., 2008). Constitutive levels of ectodomain release of proteins can 
be upregulated by the addition of phorbol esters and inhibition in the presence of TAPI 
implicates metalloprotease activity, mainly due to members of the ADAMs family.  
  
LDLr shedding was previously shown to be upregulated by phorbol esters in CHO cells 
(Begg et al., 2004). Certain candidate sheddases of the LDLr were eliminated by 
investigating the effect of inhibitors on its shedding. Furthermore, a metalloprotease was 
implicated to be responsible for the ectodomain release of the LDLr, as the shedding was 
shown to be sensitive to a hydroxamate inhibitor. TACE is an extensively studied 
metalloprotease that has many substrates (Huovila et al., 2005; Edwards et al., 2008), and 
was thought to play a role in LDLr ectodomain release since data from a proteomics 
study showed that TACE KO cells produced less soluble LDLr than the wild-type cells 
(Guo et al., 2002). 
 
The aim of this chapter was to further investigate the role of TACE in LDLr shedding. 
Therefore, wild-type (named TACE+/+ hereafter) and TACE knockout (named TACE-/- 
hereafter) mouse fibroblasts expressing LDLr constructs were analysed for ectodomain 
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release. The rationale for including the 792-LDLr and JD-LDLr constructs in this chapter 
was to identify the role TACE plays in the shedding of these constructs. These 
internalisation mutant LDLr constructs were investigated previously and showed higher 
levels of shedding when compared to the wild-type, which suggested that the shedding of 
the LDLr was not dependent on endocytosis or that the mutant LDLr was possibly shed 
by a different sheddase to the wild-type LDLr (Begg et al., 2004). The TACE-/- mouse 
fibroblasts are deficient in TACE activity since the mature TACE expressed in these cells 
lacks the zinc binding motif in the catalytic site (Black et al., 1997; Peschon et al., 1998). 
Cells were also tested in the presence of PDBu, a phorbol ester, and a stimulator of 
shedding, to determine the role of TACE in the shedding of LDL receptors in response to 
up-regulation by phorbol ester treatment in the absence or presence of TACE. The effect 
of metalloprotease inhibition in the presence of phorbol was also tested to determine the 
role of hydroxymate sensitive metalloproteases in the stimulated shedding of the LDLr in 
the absence or presence of TACE. All cell lines were stably transfected with the LDLr, 




5.2.1 Shedding of the LDLr constructs in TACE-/- mouse fibroblasts  
TACE-/- mouse fibroblasts expressing LDLr constructs were assessed for the proteolytic 
release of their ectodomains in the presence or absence of PDBu and TAPI. Cell lysate 
and medium proteins were separated on SDS-PAGE (7 % gel) under non-reducing 
conditions and analysed by Western blotting. The rabbit polyclonal antibody to the LDLr 
was chosen and used for the detection of cell associated LDLr and soluble LDLr since 
this antibody could detect soluble LDLr in medium. The LDLr has a high cysteine 
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content and therefore the epitope to the LDLr antibody would be better preserved if 
samples were separated via SDS-PAGE under non-reducing conditions, as suggested by 
the suppliers.  
 
The apparent molecular weight of the LDLr under reducing conditions is ~160 kDa 
(Schneider et al., 1982). In the absence of reducing agents, the apparent molecular weight 
of the LDLr is ~130 kDa (Daniel et al., 1983). Since the LDLr is a cysteine-rich protein, 
reduction of the disulphide bonds allows the receptor to unfold and mobility on SDS-
PAGE is slowed. Similarly, the reported value for the soluble LDLr is 140 kDa under 
reducing conditions (Begg et al., 2004). 
 
Figure 5.1: Western blots showing LDLr expression in TACE -/- mouse 
fibroblasts. 
TACE-/- mouse fibroblasts expressing wt-LDLr (a), 792-LDLr (b) or JD-LDLr (c), were 
incubated with Optimem for 4 hours at 37°C, in the presence or absence of 1 µM PDBu or 
1 µM PDBu + 10 µM TAPI. Cell lysate and medium proteins were analysed under non-
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Full length (~130 kDa) and soluble (~110 kDa) forms of the LDLr were detected in the 
cell lysates and medium samples of TACE-/- mouse fibroblasts expressing the LDLr 
constructs (Fig. 5.1). The LDLr bands detected in the cell lysate were similar in size as 
reported in the literature. The soluble LDLr in the media was ~20 kDa less than the full 
length LDLr (as reported previously) (Begg et al., 2004). Both the membrane and soluble 
forms of the LDLr were up-regulated in response to PDBu. Untransfected cells were not 
shown as a control, as the antibody does not detect LDLr in this cell line (data not 






















Figure 5.2: Soluble LDLr production in TACE-/- mouse fibroblasts. 
X-ray films of Western blots were scanned and analysed by densitometry using the 
GeneSnap and GeneTools, respectively. % soluble LDLr is expressed as a % of total 
LDLr (cell associated and medium). Results are the average of 2 independent 
experiments. The error bars indicate the range. 
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The shedding of the LDLr in TACE-/- mouse fibroblasts was quantified using 
densitometric scanning (Fig. 5.2). A constitutive level of ectodomain release of the wt-
LDLr, 792-LDLr and JD-LDLr constructs occurred in TACE-/- mouse fibroblasts 
(Figures 5.1 and 5.2). Levels of the wt-LDLr shedding were higher than the mutant 
receptors under these unstimulated conditions. In Figure 5.1, medium samples in the 
presence of PDBu, showed an increase in soluble LDLr levels over untreated conditions. 
However, when expressed as a % of total LDLr, the values were normalised (Fig.5.2), 
since an increase in the cell expression of LDLr in the presence of PDBu also occurred 
(Fig.5.1). In the presence of phorbol, shedding levels of the wt-LDLr and 792-LDLr did 
not increase as compared to unstimulated conditions, while the JD-LDLr shedding was 
stimulated ~3-fold by phorbol. TAPI decreases shedding of wt-LDLr and 792-LDLr as 
compared to untreated conditions by 1.7 and 2-fold, respectively, indicating and that the 
TAPI was inhibiting constitutive activity. This further supports that PDBu stimulated 
shedding of the wt-LDLr and 792-LDLr was TACE dependent, since in the absence of 
TACE, no increase in phorbol-stimulated shedding was observed. In the presence of 
TAPI, the phorbol-stimulated shedding of the JD-LDLr construct was decreased to 
constitutive levels. It can be concluded that in the absence of TACE, the constitutive 
level of shedding observed in mouse fibroblasts is due to another secretase or other 
secretases present in this cell line.   
 
To verify the role TACE has in the nonstimulated and stimulated levels of soluble LDLr 
production, levels of soluble LDLr in TACE deficient cells needed to be compared to 
levels in TACE+/+ mouse fibroblasts.   
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Using the calcium phosphate as a transfection method, numerous attempts to introduce 
stable LDLr over-expression into TACE+/+ mouse fibroblasts were unsuccessful. In 
these instances, resistant colonies were selected with Hygromycin, picked and 
propagated only to show no LDLr expression as assessed by Western blot. Other 
transfection methods, which yielded higher transfection efficiencies, such as transfection 
with Fugene or electroporation, also showed no LDLr expression in TACE+/+ mouse 
fibroblasts.  
 
A different strain of wild-type mouse fibroblasts was later used for the transfection of 
LDLr DNA. However, several attempts at expressing LDLr using either calcium 
phosphate or Fugene methods for transfection were unsuccessful.  
 
To circumvent this problem, the author opted to use the episomal vector BCMGSNeo 
(Karasuyama et al., 1990; Suzuki et al., 1997a). This vector confers Neomycin resistance 
to transfected cells and the vector does not incorporate into the cell’s genome, thus 
increasing the chances of improving transfection efficiency.  
 
The LDLr constructs were subcloned into BCMGSNeo and transfected into TACE+/+ 
mouse fibroblasts. The mouse fibroblasts were transfected using calcium phosphate but 
did not produce any clones, when selected with 0.8 mg/ml Geneticin.  
 
A third source of TACE+/+ mouse fibroblasts yielded the same results when transfected, 
i.e. the cells died and no clones were formed during selection. More stable transfections 
were attempted, reducing the concentration of Geneticin to 0.35 mg/ml in the medium. 
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This time, after a week of selective medium the mouse fibroblasts formed clones but 
when picked, they did not grow.  
 
To provide evidence that the LDLr construct in the BCMGSNeo vector could be 
expressed in mammalian cells, CHO cells were stably transfected with the LDLr in 






CHO cells transfected with the LDLr constructs in the BCMGSNeo vector, produced 
resistant clones which stably expressed LDLr as assessed by Western blot (Fig. 5.3).  The 
LDLr expressed here is of the same molecular weight as seen before in TACE-/- mouse 
fibroblasts (Fig. 5.1).  
Figure 5.3: Western blot showing LDLr expression in a 
CHO A7 clone. 
CHO A7 cells were stably transfected with BCMGSNeo-LDLr. 
~30 µg cell lysate of untransfected CHO A7. A CHO A7 clone 
was loaded on a SDS-PAGE (7% gel) and assessed for LDLr 
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GFP was used to determine if TACE+/+ mouse fibroblasts could be transfected with 
another construct. To compare transfection efficiencies of mouse fibroblasts, TACE-/- 




A number of TACE-/- mouse fibroblasts, seen as clusters of cells in Figure 5.4 (b), 
showed GFP expression while the TACE+/+ mouse fibroblasts failed to express GFP 
under the same conditions [Fig. 5.4 (c).]. This suggested that the transfection efficiency 
of TACE+/+ was lower than the TACE-/- counterparts. From all the transfection 
experiments, it was evident that expression of both the LDLr and GFP was problematic 
in TACE+/+ mouse fibroblasts.  
 
After numerous unsuccessful attempts to transfect LDLr constructs into wild-type mouse 
fibroblasts, another approach was investigated to compare shedding of the LDLr in a 
TACE null cell line.  
Untransfected pcGFP(s) pcGFP(s) 
10 X 
(a). (b). (c).  
Figure 5.4: GFP expression in TACE-/- and TACE+/+ mouse fibroblasts. 
(a). Untransfected TACE-/- mouse fibroblasts. (b). TACE-/- mouse fibroblasts. (c). 
TACE+/+ mouse fibroblasts. Cells were transfected with pcGFP(s) by the calcium 
phosphate method. 72 hours after transfection, non-fixed cells were visualised by 
fluorescent microscopy.  
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5.2.2 Shedding of LDLr constructs in CHO M2 and CHO A7 cells 
The other approach was to investigate shedding in a CHO M2 cell line, which only 
produced the inactive prodomain of TACE (Borroto et al., 2003). This cell line was 
chosen so that shedding levels of the LDLr constructs in this TACE deficient cell line 
could be compared to LDLr shedding in CHO A7 cells (Begg et al., 2004). CHO A7 cells 
do not express endogenous LDLr. CHO M2 cells have endogenous LDLr expression but 
the levels are low that the LDLr cannot be detected by Western blotting, using the 
conditions used in this study.  
 
The TACE-/- mouse fibroblasts are able to produce both the prodomain as well as mature 
TACE which remains inactive due to the mutation in the zinc-binding catalytic site 
(Black et al., 1997; Peschon et al., 1998). The CHO M2 cell line is different to the 
TACE-/- mouse fibroblasts in that the CHO M2 cell line is a chemically mutated cell line 
that is deficient in the shedding of the TGF-α (Arribas and Massague, 1995). The 
shedding of APP, pro-HB-EGF and L-selectin was also defective in CHO M2. In a later 
publication, it was revealed that the cell line was defective in producing active TACE, 
since only the prodomain is made in these cells as a result of aberrant transport of TACE 
out of the secretory pathway (Borroto et al., 2003). Trafficking of other ADAMs such as 
ADAM 9, ADAM 10 or MT1-MMP appear to be normal in these cells, since all the 
furins are present in these cells, making the defect specific for TACE. In addition, CHO 
M2 cells were shown to produce two TACE variants that have mutations in the catalytic 
domain as well as the cysteine-rich disintegrin domain (Li and Fan, 2004). The mutation 
present in the cysteine-rich disintegrin domain was shown to be important with respect to 
the loss of TACE activity.  
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A comparison of TACE expression in TACE-/- mouse fibroblasts and CHO M2 cells is 
seen in Figure 5.5. The TACE antibody detected two bands in the TACE-/- mouse 
fibroblasts, a higher molecular weight component of ~100 kDa, representing the 
unprocessed inactive prodomain of TACE, and a lower molecular weight component of 
75 kDa, corresponding to the processed, mature form of TACE (Fig. 5.5). However, the 
mature, processed form seen here is inactive due to the lack of the zinc binding motif in 
the catalytic site (Black et al., 1997; Peschon et al., 1998). The molecular weights 
detected here corresponded to the values provided in the literature (Borroto et al., 2003). 
In the CHO M2 cell line, the TACE antibody mainly detects the prodomain and a faint 
lower molecular weight band can just be seen. This may be due to some minor 
processing of TACE in these cells. 
Figure 5.5: Western blot showing expression of TACE in CHO M2 
cells and TACE-/- mouse fibroblasts. 
40 µg of cell lysates of CHO M2 cells and TACE-/- mouse fibroblasts were 
loaded on SDS-PAGE (7 % gel) under non-reducing conditions and analysed 
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Stable cell lines of CHO A7 and CHO M2 cells expressing LDLr constructs were made 
by the calcium phosphate method of transfection. Shedding of the LDLr constructs was 
assessed in the CHO A7 cell line (Fig. 5.6). Cellular and soluble forms of the LDLr were 
detected in the cell lysates and medium samples of CHO A7 cells. In the presence of 
PDBu an increase in the soluble forms of wt-LDLr and 792-LDLr were seen over 
unstimulated conditions. Here the increase in cellular levels due to PDBu is not that 
evident from the Western [as seen in TACE-/- mouse fibroblasts (Fig 5.1)], since in CHO 
cells, the presence of TACE converts the membrane form to the soluble form at a higher 
rate.  
Figure 5.6: Western blots showing LDLr shedding in CHO A7 cells 
CHO A7 cells expressing wt-LDLr (a), 792-LDLr (b) or JD-LDLr (c), were incubated 
for 4 hours with Optimem at 37°C, in the presence or absence of 1 µM PDBu or 1 µM 
PDBu + 10 µM TAPI. Cell lysate and medium proteins were analysed under non-






























































Levels of LDLr shedding were quantified in CHO A7 cells (Fig. 5.7). Soluble LDLr was 
observed under all conditions assayed. Constitutive levels of ectodomain release of 792-
LDLr, and JD-LDLr in CHO A7 cells were higher than wt-LDLr as reported (Begg et al., 
2004). Cells incubated with phorbol enhanced the ectodomain release of wt-LDLr ~2-
fold, while the shedding of the 792-LDLr increased ~1.3 fold. In the presence of TAPI, 
the phorbol stimulated shedding of wt-LDLr and 792-LDLr constructs released into the 
medium was decreased to constitutive levels. Shedding of the JD-LDLr was not 





















Figure 5.7: Soluble LDLr production in CHO A7 cells. 
X-ray films of Western blots were scanned and analysed by densitometry using the 
GeneSnap and GeneTools, respectively. % soluble LDLr is expressed as a % of total 
LDLr (cell associated and medium) to normalise for variations in experession levels 
between cell lines. Results are the average of 2 independent experiments. The error bars 
indicate the range.  
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Shedding of the LDLr constructs was assessed in the CHO M2 cell line (Fig. 5.8). 
Cellular and soluble forms of the LDLr were detected in the cell lysates and medium 
samples of CHO M2 cells expressing LDLr constructs. Medium levels of the LDLr were 
low or hardly detectable. Soluble LDLr levels in the CHO M2 cell line were lower than 
in the CHO A7 cell line and TACE-/- mouse fibroblasts. There was a slight increase in 
the cellular LDLr expression in the presence of PDBu, but no associated increase in 
soluble LDLr ectodomain was observed. 
 
Figure 5.8: Western blots showing LDLr shedding in CHO M2 cells. 
CHO M2 cells expressing wt-LDLr (a), 792-LDLr (b) or JD-LDLr (c), were 
incubated for 4 hours with Optimem at 37°C, in the presence or absence of 1 µM 
PDBu or 1 µM PDBu + 10 µM TAPI. Cell lysate and medium proteins were 
analysed under non-reducing conditions by Western blotting. The Westerns 
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Shedding of the LDLr constructs in CHO M2 cells were quantified by densitometry (Fig. 
5.9). The programme used for densitometry could detect low levels of soluble LDLr, 
which was slightly above background. Levels of LDLr shedding were low in CHO M2 
cells, and all the LDLr constructs showed a similar shedding pattern, i.e., no increase in 
soluble LDLr was seen in the presence of PDBu (Fig. 5.9) The presence of phorbol 
increased cellular expression, but no associated increase in soluble LDLr was seen (Fig. 
5.8, and Fig. 5.9). In addition, TAPI in the presence of phorbol seemed to decrease wt-
LDLr and JD-LDLr shedding to lower than constitutive levels. TAPI did not have an 
effect on the levels of 792-LDLr shedding. 
 
When shedding levels of LDLr was compared between the CHOM2 cells and the TACE-















Figure 5.9: Soluble LDLr production in CHO M2 cells. 
X-ray films of Western blots were scanned and analysed by densitometry using the 
GeneSnap and GeneTools, respectively. % soluble LDLr is expressed as a % of 
total LDLr (cell associated and medium). Results are the average of 2 independent 
experiments. The error bars indicate the range. 
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fold lower in the CHO M2 cells than the TACE-/- mouse fibroblasts (Figures 5.1 and 5.2, 
compared to Figures 5.8 and 5.9).  
 
Constitutive levels of the wt-LDLr, 792-LDLr, and JD-LDLr in the CHO M2 cells were 
approximately 6-fold, 19-fold and 33-fold less, respectively, than in the CHO A7 cells 
(compare Figures 5.7 and 5.9). In the presence of phorbol, shedding of the wt-LDLr, 
792-LDLr, and JD-LDLr were approximately 22-fold, 25-fold and 26-fold less, 
respectively, in the CHO M2 cells compared to the CHO A7 cells. Thus, in CHO M2 
cells, constitutive and phorbol stimulated shedding of the wt-LDLr, 792-LDLr and JD-
LDLr was TACE dependent. 
 
5.2.3 Comparison of TACE-/- mouse fibroblasts to CHO M2 cells 
From the Western blot and shedding results, it appeared that the production of the soluble 
LDLr was more than 5-fold higher in the TACE-/- mouse fibroblasts when compared to 
the CHO M2 cells (Figures 5.2 and 5.8). Initially, it was thought that this could be due to 
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A TACE-/- mouse fibroblast cell line expressing LDLr at a slightly lower level than a 
CHO M2 cell line was assessed for shedding (Fig. 5.10).  The results indicated that 
higher shedding levels of LDLr were produced in the TACE-/- mouse fibroblasts than in 
the CHO M2 cell line, and was not due to higher LDLr expression levels. 
  
This finding led the author to consider the fact that the TACE-/- mouse fibroblasts might 
have higher non-TACE sheddase activity than in the CHO M2 cell line. To investigate 
the possibility, a fluorogenic peptide substrate that spans the TNF-α stalk region, was 
utilised as it was possible to assess TACE, or other sheddase activity, in mammalian cells 





































TACE-/- mouse fibroblasts  CHO M2 cells 
(a). (b). 
Figure 5.10: Western blots showing a comparison of soluble LDLr 
production in TACE KO cell lines. 
Cells were incubated with Optimem for 4 hours. 40 ug of cell lysate and an 
equal volume of medium of TACE-/- mouse fibroblasts and CHO M2 cells 
were separated under non-reducing conditions on a SDS-PAGE (7 % gel) and 
detected with the antibody to the LDLr.  
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The TNF-α stalk is flanked by a fluorescent donor (ortho-aminobenzoic acid; Abz) and a 
fluorescent acceptor (2, 4 dinitrophenol; Dnp) (Fig. 5.11). When the intact peptide is 
excited at 320 nm, the acceptor quenches the fluorescence emitted by the donor. When 
the peptide is cleaved, the fluorescence emitted by the donor is not quenched when 
excited, and there is an increase in fluorescence that can be measured continuously.  
 
Peptides spanning the TNF-α stalk peptide were cleaved by recombinant TACE, as well 
as purified ADAM 9, ADAM 10, MMP-7 and ADAM 19 (Rosendahl et al., 1997; 
Figure 5.11: Schematic representation of the mechanism of the fluorogenic 
peptide assay 
(a). Intact peptide when excited at 320 nm did not emit fluorescence, as the acceptor (Dnp) 
quenched the fluorescence emitted by the donor (Abz).  
(b). When the peptide was cleaved, the fluorescence emitted by the donor (Abz) was not 
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Roghani et al., 1999; Chesneau et al., 2003; Zheng et al., 2004). Other MMPs like MMP-
1, MMP-9 and MMP-13 were also able to cleave this peptide (Jin et al., 2002). 
 
 
To assess and compare shedding activies in the two TACE deficient cell lines, equal 
amounts of total protein from cell lysates of TACE-/- mouse fibroblasts and CHO M2 
cells were used. The fluorescence intensity over the experimental time period was higher 
in TACE-/- mouse fibroblasts compared to CHO M2 cells (Fig. 5.12). At initial rates 
(within 10 % peptide hydrolysis), the rates of cleavage by TACE-/- and CHO M2 cell 
lysate were calculated to be 0.43 pmol/min/µg and 0.176 pmol/min/µg, respectively. The 
rate of the cleavage of the fluorogenic TNF-α stalk peptide was ~2.4-fold higher in the 
TACE -/- mouse fibroblasts than in the CHO M2 cells. This indicated that non-TACE 
Figure 5.12: Cleavage of TNF-α stalk peptide by TACE-/- mouse fibroblasts and 
CHO M2 cell lines. 
100 µg of cell lysates of TACE-/- mouse fibroblasts, heat inactivated TACE-/- mouse 
fibroblasts and CHO M2 were assayed for cleavage of the TNF-α stalk peptide at 37°C, 
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sheddase activity was higher in TACE-/- mouse fibroblasts than in CHO M2 cells, which 
implicated other ADAMs that cleaved the TNF-α stalk peptide to be present at a higher 
level in the TACE-/- mouse fibroblasts, or that there were other sheddases present in the 
mouse fibroblasts that were not found in the CHO M2 cells. The possible candidates that 
could play a role are ADAM 9 and/or ADAM 10, as these ADAMs also cleave the TNF-
α stalk peptide. In addition, these ADAMs play a role in the shedding of some other 
TACE substrates such as APP and HB-EGF (Izumi et al., 1998; Lammich et al., 1999). 
Thus there might be increased levels of ADAM 9 and/or ADAM 10 expression in the 
TACE-/- mouse fibroblasts compared to the CHO M2 cells. The increased soluble LDLr 
production in these cells could be attributed to this phenomenon, as these ADAMs may 
also play a role in the shedding of the LDLr.   
 
To investigate the possibility that ADAM 9 and/or ADAM 10 expression was higher in 
TACE-/- mouse fibroblasts compared to that of CHO M2, equal amounts of cell lysates 
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The antibody to ADAM 9 detected two bands in the cell lysate of CHO M2 and TACE-/- 
mouse fibroblasts (Fig.5.13). The unprocessed, intact prodomain form was seen at ~120 
kDa and the processed mature form of ADAM 9 was seen at ~90 kDa (Borroto et al., 
2003). In CHO M2 and TACE-/- mouse fibroblasts, both the prodomain and mature 
forms of ADAM 9 were detected. Expression levels for both the prodomain and the 
mature forms of ADAM 9 were similar in TACE-/- mouse fibroblasts and CHO M2 
cells. This excludes the possibility that ADAM 9 was responsible for the increased 



























Figure 5.13: Western blot showing ADAM 9 expression in CHO M2 
cells and TACE-/- mouse fibroblasts. 
40 µg of non-reduced cell lysates of the CHO M2 cells and TACE-/- mouse 
fibroblasts were loaded onto 7% SDS-PAGE and analysed by Western blotting 
for ADAM 9 expression, using the polyclonal antibody to ADAM 9. 
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The antibody to ADAM 10 detected the unprocessed inactive prodomain with a 
molecular weight of ~130 kDa and the processed mature active form of ADAM 10 with a 
molecular weight of 85 kDa in TACE-/- mouse fibroblasts (Fig. 5.14). Very low levels of 
the prodomain form of ADAM 10 levels were seen in the CHO M2 cells. ADAM 10 
expression was found to be higher in TACE-/- mouse fibroblasts than in the CHO M2 
cells, as indicated by the higher levels of both the prodomain and the mature ADAM 10 
forms (Fig. 5.14). When the blot was quantified by densitometry, mature ADAM 10 
levels in TACE-/- mouse fibroblasts were ~2.7-fold higher than in CHO M2 cells.  
 
From these data, we can conclude that both forms of ADAM 10 were expressed at higher 
levels, which could account for higher fluorescence activity seen in the TNF-α peptide 





























Figure 5.14: Western blot showing ADAM 10 expression in CHO M2 
cells and TACE-/- mouse fibroblasts. 
40 µg of non-reduced cell lysates of the CHO M2 cells and TACE-/- mouse 
fibroblasts were loaded onto 7% SDS-PAGE and analysed by Western blotting for 
ADAM 10 expression, using the polyclonal antibody to ADAM 10. 
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fibroblasts. This ADAM 10 could play a role in the shedding of the LDLr, since this 
ADAM is the most closely related to TACE and has similar substrate requirements 
(Killar et al., 1999; Rosendahl et al., 1997; Huovila et al., 2005; Reiss and Saftig, 2008; 
Reddy et al., 2000).   
 
5.2.4 ADAM 10 as a potential sheddase 
Since an increase in ADAM 10 expression was seen in the TACE-/- mouse fibroblasts, it 
is possible that this ADAM could be responsible for the shedding of LDLr in these cells. 
To determine if an association between ADAM 10 and the LDLr could be established, 
cell lysates of TACE-/- cells were co-immunoprecipitated using the C7 monoclonal 
LDLr antibody to immunoprecipitate the lysate, and the immunoprecipitate was further 
probed in a Western blot with the ADAM 10 antibody. In addition, cells were cross-
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As a control for the experiment, the Western blots were probed with the rabbit polyclonal 
antibody to the LDLr. Samples were separated on SDS-PAGE (7 % gel) and Western 
blots were analysed for LDLr or ADAM 10 expression, using the rabbit polyclonal 
Figure 5.15: Schematic representation of the identification of LDLr cell surface 
associated proteins by Western blot with cross-linking and IP. 
(i). Cells are lysed (a) and subjected to IP (b). Complexes are separated by SDS-PAGE and 
probed with the LDLr antibody or the ADAM 10 antibody.  
(ii). Surface proteins are cross-linked prior to lysis (a), to increase the probability of 
complex formation, since proteins in close proximity will be cross-linked. The cross-linked 
cells are subjected to IP and complexes are analysed by western blot with the LDLr 
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antibody to the LDLr or the rabbit polyclonal antibody to ADAM 10, respectively. 
Detection using the LDLr antibody served as a control for the experiment, to show that 
the IP and/or cross-linking were successful.   
 
 
In Fig 5.16, the LDLr was detected in LDLr expressing cells only. Here all the samples 
were reduced, and the LDLr migrated with a relative mobility (Rf) value that 
corresponded to ~160 kDa. When the cells were cross-linked, an LDLr oligomer was 
detected, in addition to the monomer, as reported previously (van Driel et al., 1987). The 
immunoprecipitated sample showed comparable LDLr levels, indicating that the IP was 
successful. The controls for the experiment were untransfected, non-cross-linked TACE-
/- cells. No LDLr was detected in all of the untransfected TACE-/- cell lysate samples. 
Figure 5.16: Cross-linking and IP of wt-LDLr in TACE-/- mouse fibroblasts. 
Untransfected and wt-LDLr expressing cells were lysed, or cross-linked prior to cell lysis 
or cross-linked prior to cell lysis and IP. Non-cross-linked cell lysate was IP as a control. 
The monoclonal antibody the LDLr (IgG-C7) was used for the IP, while the LDLr was 
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When the cells were cross-linked prior to lysis followed by IP, the monomer and 
oligomer were detected with the pull down, indicating that the band seen in those cross-
linked samples were specific to the LDLr antibody. Thus, the IP of wt-LDLr as well as 
the cross-linking were successful in TACE-/- mouse fibroblasts. 
 
 
To determine if ADAM 10 co-immunoprecipitated with the LDLr, the same samples 
were probed with the ADAM 10 antibody (Fig. 5.17). The prodomain and mature forms 
of ADAM 10 were seen in untransfected as well as LDLr-transfected TACE-/- cells. 
Cross-linking prior to cell lysis had no effect on the ADAM 10 forms, that is, no dimer 






















































































Mature ADAM 10 
Figure 5.17: Cross-linking and co-immunoprecipitation of wt-LDLr and 
ADAM 10 in TACE-/- mouse fibroblasts. 
Untransfected and wt-LDLr expressing cells were lysed, or cross-linked prior to cell lysis 
or cross-linked (X-link) prior to cell lysis and immunoprecipitated. Non-cross-linked cell 
lysate was immunoprecipitated as a control. The monoclonal antibody the LDLr (IgG-
C7) was used for the IP, while the ADAM 10 was detected in the Western blot with the 
rabbit polyclonal antibody to the ADAM 10. All the samples contained β-ME. 
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untransfected and LDLr-transfected cells. Cross-linking prior to cell lysis, followed by IP 
showed no ADAM 10 in the untransfected and LDLr-transfected cells.  
 
From Figure 5.16, it was shown that the IP as well as cross-linking were successful, 
indicating that in Figure 5.17, the IP with the anti-LDLr did not show any association 
with ADAM 10 when the samples were probed with the ADAM 10 antibody. 
Furthermore, cross-linking prior to IP showed no enhancement of an interaction. Apart 
from the LDLr band and an LDLr oligomer band in Figure 5.16, no other bands were 
detected that could be attributed to an ADAM 10-LDLr complex. Similarly, when the 
ADAM 10 antibody was used there were no higher molecular weight bands in the cross-




One of the main findings of this chapter indicated that in mouse fibroblasts there were 
constitutive levels of soluble LDLr production in the absence of TACE. Soluble levels of 
the wt-LDLr and 792-LDLr were not stimulated by phorbol, suggesting dependence on 
TACE activity. In CHO cells, constitutive and phorbol-stimulated shedding of wt-LDLr, 
792-LDLr and JD-LDLr were dependent on TACE activity.  
 
Using different transfection methods to obtain LDLr expression in TACE+/+ mouse 
fibroblasts produced antibiotic resistant clones that failed to express LDLr. In addition, 
GFP expression also failed in TACE+/+ mouse fibroblasts (Fig. 5.4). Transfection and 
expression of ACE in TACE+/+ mouse fibroblasts was also unsuccessful (unpublished 
results, Schwager). Since the GFP construct is not dependent on shedding, it served as a 
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control for determining transfection efficiencies between the two cell lines. The 
transfection efficiencies between TACE+/+ and TACE-/- mouse fibroblasts have been 
reported to be different and therefore a reporter gene was used as a correction factor 
(Tsakadze et al., 2006). In another study, TACE+/+ mouse fibroblasts have been reported 
to have a lower transfection efficiency than the TACE-/- counterparts (Zhao et al., 2003). 
As yet, no other explanation why the TACE+/+ mouse fibroblasts have lower 
transfection efficiencies than the TACE-/- mouse fibroblasts has been found.  
 
Efficient transfection of mammalian cells depends on adequate uptake of foreign DNA 
into the nucleus (Byrnes et al., 2002). In most cell types DNA uptake into the cytoplasm 
is efficient, but not enough enters the nucleus. The presence of a nuclear targeting 
peptide during lipid-mediated transfection enhances protein expression in wild-type 
mouse fibroblasts. Perhaps wild-type mouse fibroblasts have a lower nuclear uptake of 
foreign DNA compared to other cells.  
 
Shedding of the LDLr constructs in TACE deficient mouse fibroblasts showed that 
constitutive levels of LDLr release occurred in the absence of TACE activity (Figures 5.1 
and 5.2). However, without knowing the constitutive levels of LDLr shedding in 
TACE+/+ mouse fibroblasts it could not be concluded that the constitutive shedding was 
not dependent on TACE, since if constitutive levels were the same in both cell types, 
then the ectodomain release of the LDLr was not TACE dependent. Constitutive levels of 
soluble wt-LDLr and 792-LDLr were not stimulated by PDBu. This suggested that the 
sheddases that were responsible for the shedding of wt-LDLr and 792-LDLr in TACE-/- 
mouse fibroblasts do not increase soluble LDLr in the presence of phorbol. TAPI in the 
presence of PDBu decreased soluble LDLr levels to less than that of constitutive levels. 
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This suggested that TAPI was inhibiting constitutive metalloprotease activity that 
contributed to the cleavage of wt-LDLr and 792-LDLr. The internalisation mutants did 
not undergo increased constitutive shedding as expected when compared to the wt-LDLr, 
as shown previously in CHO cells. This suggested that internalisation of the LDLr does 
not have an effect on the shedding of the receptor in TACE-/- mouse fibroblasts. These 
data indicate that phorbol-stimulated shedding was dependent on TACE activity in 
mouse fibroblasts, but levels needed to be compared to those found in TACE+/+ mouse 
fibroblasts to confirm this event. The JD-LDLr showed ~3-fold sensitivity to phorbol, 
and TAPI decreased the phorbol-stimulated release to that of constitutive levels. This 
indicated that another sheddase(s) might be involved in the shedding of the JD-LDLr. 
However, there was no shedding data available from TACE+/+ mouse fibroblasts to 
compare levels to validate this claim.  
 
Higher levels of both the cell associated and soluble TNF-α were seen in TACE-/- mouse 
fibroblasts compared to TACE+/+ mouse fibroblasts (Zhao et al., 2003). However when 
% shedding was determined, the normalised values for TACE+/+ fibroblasts indicated 
higher soluble TNF-α levels. The same phenomenon could apply to the data seen in 
Figures 5.1 and 5.2., where if levels were to be compared to TACE+/+ fibroblasts, a 
dependence of TACE activity could be implicated in both the constitutive and stimulated 
shedding of the LDLr. Therefore, shedding levels of the LDLr was assessed in another 
TACE null cell line to determine the role of TACE in the ectodomain release of the 
LDLr. 
 
In CHO cells, shedding of the wt-LDLr, 792-LDLr and JD-LDLr has been previously 
shown to be increased significantly by phorbol stimulation (Begg et al., 2004). The 
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experiments here indicated that there was a ~2-fold increase in soluble wt-LDLr and a 
~1.3-fold increase in soluble 792-LDLr levels compared to constitutive levels when 
stimulated with phorbol (Fig. 5.7). Levels of soluble JD-LDLr did not increase in the 
presence of phorbol. It was possible that the differences in the ectodomain shedding here 
compared to Begg et al., could be due to the use of a different vector (pLDLr2), a 
different transfection method (co-transfection with pSV3Neo), a different method of 
detecting LDLr ([35S] methionine labelled cells and IP with IgG-C7) and a different 
quantification programme used for densitomtery (Begg et al., 2004). Begg et al. (2004), 
detected LDLr expression was detected by labelling cells with [35S] methionine, which 
resulted in the synthesis of radioactively labelled protein. When cell and medium 
samples were immunoprecipitated with the C7 monoclonal antibody, it bound to the 
LDLr present in that sample. IgG-C7-LDLr complexes were reduced and separated by 
SDS-PAGE. Proteins were transferred to nitrocellulose membranes and bands were 
detected by autoradiography. The affinity of the rabbit polyclonal antibody could 
possibly have a different affinity for the soluble LDLr compared to the monoclonal C7 
antibody used previously. The expression vector used by Begg et al. (2004) was driven 
by the SV40 promoter, whereas the vector used here was driven by a CMV promoter. 
The CMV promoter was more sensitive to phorbol stimulation (Clesham et al., 1996; 
Maass et al., 2003; Mehta et al., 2009) hence an increase in cellular LDLr levels was seen 
(Figures 5.1, 5.6 and 5.8). In addition, the cellular pool of LDLr was decreased with the 
concomitant increase of soluble LDLr in response to PMA (Begg et al., 2004). However, 
the author did not observe this effect in CHO cells, as an increase in the LDLr cellular 
levels together with increased LDLr release occurred (Fig. 5.8).  
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Shedding of the LDLr constructs was at least 5-fold lower in the CHO M2 cells 
compared to the TACE-/- mouse fibroblasts (Fig 5.9 and Fig. 5.2). In addition, 
constitutive shedding of the LDLr constructs in the CHO M2 cells was more than 6-fold 
lower than in the CHO A7 cells, while stimulated shedding was more than 20-fold lower 
(Fig. 5.7 and Fig. 5.9). Levels of 792- and JD-LDLr release were not higher than wt-
LDLr in the CHO M2 cells. The same was seen in the TACE-/- mouse fibroblasts, 
indicating that internalisation does not influence the shedding in TACE deficient cells. It 
was expected that the constitutive shedding levels of the mutants would be higher, but it 
could be different here due to the different methods used as explained before. Levels of 
soluble LDLr in the two CHO cell lines indicate that both the constitutive and phorbol-
stimulated shedding of LDLr constructs were dependent on TACE activity.  
 
A number of proteins that undergo proteolytic cleavage to release ectodomains have also 
been suggested to release the ICD of the C-terminal membrane embedded fragment, 
similar to Notch-1 and APP processing (Beel and Sanders, 2008). In addition, members 
of the LDLr family such as the LRP-1, ApoE R2 and vLDLr have been shown to 
undergo release of the ICD following ectodomain cleavage (May et al., 2002; Rebeck et 
al., 2006). Recently, a few proteins, in addition to the LDLr were identified by stable 
isotope labelling with amino acids in cell culture (SILAC) and proteomic profiling, to be 
novel substrates of the γ-secretase (Hemming et al., 2008). Cells in the presence of 
DAPT (an inhibitor of the γ-secretase) were labelled with the light isotope label while 
DMSO-treated cells were labelled with the heavy isotope. In the presence of DAPT, an 
increase in the C-terminal fragment was seen since it was not cleaved to release the ICD, 
and this difference could be seen when relative abundance of peptides between the two 
conditions were measured by liquid chromatography mass spectrometry (LC-MS). 
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However, only one peptide corresponding to the LDLr was identified in this way. In 
addition, the LDLr was not studied further by over-expression in mammalian cells like 
the other proteins identified by the authors of that publication. As a result, the LDLr was 
not confirmed as a γ-secretase substrate. In another study, the LDLr was also investigated 
in addition to LRP-1 for the release of ICD, except that the release of an ICD fragment of 
the LDLr was shown not to occur (May et al., 2002; May et al., 2003). Therefore, more 
experiments need to be performed to investigate whether the LDLr also undergoes 
sequential cleavage like Notch-1 processing and like other LDLr family members. It 
would be of interest to test if the C-terminal fragment of the LDLr undergoes 
intramembrane proteolysis. The accumulation of the C-terminal fragment of the LDLr 
could be investigated in the presence of DAPT for future work, to confirm the LDLr as a 
γ-secretase substrate.  
 
When soluble LDLr levels were compared between the two TACE deficient cells lines, 
the TACE-/- mouse fibroblasts showed higher soluble LDLr production than the CHO 
M2 cells. It was thought that there might be more sheddase activity in the TACE-/- 
mouse fibroblasts than the CHO M2 cells. To investigate sheddase activity in the TACE 
deficient cell lines, cell lysates were tested for the cleavage of the TNF-α stalk peptide. 
From the TNF-α stalk peptide cleavage assays, TACE-/- mouse fibroblasts were shown 
to be ~2.4-fold more efficient than the CHO M2 cells at cleavage (Fig. 5.12). This 
suggested that there were other non-TACE sheddases present in mouse fibroblasts that 
were not in the CHO M2 cells, or that there were different levels of expression of 
different sheddases. Of the sheddases that cleave the TNF-α stalk peptide, ADAM 9 and 
ADAM 10 were chosen as candidate sheddases for further investigation, as these 
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ADAMs were also studied as alternative sheddases for TACE substrates (Rosendahl et 
al., 1997; Roghani et al., 1999; Vincent et al., 2001; Deuss et al., 2008). 
 
ADAM 9 expression levels were the same in TACE-/- mouse fibroblasts and CHO M2 
cells (Fig. 5.13), suggesting that this sheddase might not contribute to increased cleavage 
of the TNF-α stalk peptide in these cells. ADAM 10 expression levels were ~2.7-fold 
higher in TACE-/- mouse fibroblasts than in the CHO M2 cells (Fig. 5.14), implicating 
ADAM 10 as a candidate sheddase responsible for TNF-α cleavage in TACE-/- mouse 
fibroblasts. Since ADAM 10 is the most closely related to TACE in terms of sequence 
and substrate specificities (Killar et al., 1999; Rosendahl et al., 1997; Edwards et al., 
2008), it was thought that ADAM 10 might play a role in the shedding of the LDLr in 
TACE-/- mouse fibroblasts.  
 
To investigate whether ADAM 10 was associated with or interacted with the LDLr in 
TACE-/- mouse fibroblasts, co-immunoprecipitation studies were performed. Co-
immunoprecipitation was used previously to provide evidence of ADAM 10 and ADAM 
10 substrate association (Hattori et al., 2000; Gavert et al., 2007; Lemieux et al., 2007). 
In Fig. 5.16, the LDLr was detected in the LDLr expressing cells and in the presence of a 
cross-linker, an oligomer was formed. Both the cross-linking and IP were successful as 
shown by the LDLr band and the oligomer band (Fig. 5.16). No ADAM 10 was detected 
in the LDLr immunoprecipitated samples when the ADAM 10 antibody was used to 
detect ADAM 10 interactions (Fig. 5.17). These results suggested that either ADAM 10 
was not involved in the shedding of the LDLr, at least in the case of the wt-LDLr in the 
absence of TACE, or that the association between the ADAM 10 and the LDLr was not 
long enough for the detection thereof. With respect to the cross-linking, it could also 
  114 
possibly be that the cross-linker preferentially allowed LDLr-LDLr formation rather than 
the LDLr-sheddase formation, since the on-off rate between the enzyme and receptor 
could be too fast.  
 
Researchers that have used co-immunoprecipitation to illustrate interactions between 
ADAM 10 and ADAM 10 substrate have used transfected ADAM 10 constructs in their 
experiments (Hattori et al., 2000; Gavert et al., 2007; Lemieux et al., 2007). Co-
immunoprecipitation confirmed that ADAM 10 associated with ephrin-A2, a glycosyl-
phospatidylinositol (GPI)-bound membrane protein shed by ADAM 10 (Hattori et al., 
2000). For the co-immunoprecipitation, cells were co-transfected with differently tagged 
constructs, and probed with antibodies specific to the tags. As a control a GPI-anchored 
protein that was not shed by ADAM 10, did not form a complex. Co-transfection of 
tagged CD 23 and tagged ADAM 10 also indicated an association between the two 
proteins using antibodies against the tagged proteins (Lemieux et al., 2007). The 
association between a GFP-tagged L1-CAM and a tagged ADAM 10 was also shown 
(Gavert et al., 2007). It is also possible that a different co-localisation between the 
ADAM 10 and LDLr exists, compared to the proteins in the above-mentioned studies, 
which may have affected the IP. 
 
ADAM 10 is a likely candidate to investigate further. In addition, the expression of 
ADAM 19 or other MMPs could be investigated in mouse fibroblasts and could be a 
possible target for down-regulation, to determine if other sheddases have a role in the 
shedding of the LDLr. Future work that could be explored would be to assay soluble 
LDLr shedding levels in TACE-/- mouse fibroblasts in the presence of ADAM 10 
  115 
siRNA, for the specific down-regulation of ADAM 10 to determine the role ADAM 10 
has in LDLr shedding.  
 
In conclusion, the constitutive level of LDLr shedding was not totally dependent on 
TACE activity in mouse fibroblasts, while in CHO cells the shedding data showed that 
the constitutive and phorbol-stimulated production of soluble LDLr was almost 
completely dependent on TACE activity. This phenomenon was mostly due to the higher 
sheddase activity present in TACE-/- mouse fibroblasts. ADAM 10 expression was 
confirmed to be higher in TACE-/- mouse fibroblasts and is a likely candidate to 
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Chapter 6: 
Detection of soluble LDLr in human plasma 
 
6.1 Introduction 
A number of unrelated membrane-bound proteins have been found to be released by 
cleavage secretion into the medium of cultured mammalian cells (Peschon et al., 1998; 
Arribas and Borroto, 2002; Mezyk et al., 2003). Studies on the ectodomain shedding of 
proteins have provided some insight into the functions of the soluble proteins (Arribas 
and Borroto, 2002; Rebeck et al., 2006; Edwards et al., 2008). The formation of soluble 
LDLr was observed in cultured human skin fibroblasts as well as LDLr transfected CHO 
cells (Begg et al., 2004). Some soluble protein ectodomains have been found in human 
plasma, such as TNF-α, TNF-α receptors (Aderka, 1996) and other cytokines and 
receptors (Novick et al., 1992). Studying the plasma proteome is very useful for the 
evaluation of soluble proteins as biomarkers in cancers and other diseases (Aderka, 1996; 
Gattorno et al., 1996; Cavusoglu et al., 2007). The plasma proteome however is a 
complex system, as its dynamic range extends over several orders of magnitude, making 
the detection of low abundance proteins extremely difficult. A further complication is the 
small volumes of plasma used for analysis. 
 
The aim of this section of the project was to identify and characterise soluble LDLr in 
human plasma. The identification of other members of the LDLr family in plasma (Quinn 
et al., 1997) as well as the presence of a urinary LDLr (Molina et al., 2007) increased the 
possibility of finding soluble LDLr in plasma. The urinary LDLr corresponded to 
residues 4-166 of the ligand binding domain. To ascertain whether the formation of 
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soluble LDLr occured in humans in vivo, the following approaches were used: lectin 




6.2.1 Detection of soluble LDLr in plasma using lentil lectin affinity chromatography 
The rationale for using lectin affinity was that glycosylated proteins, including the 
soluble LDLr (as it is O-glycosylated), would bind to the lentil lectin Sepharose beads. 
This should result in an enrichment of the plasma glycosylated protein fraction.  
 
Human plasma was incubated with lentil lectin Sepharose beads and after washing, the 
glycoproteins were eluted. The buffer was exchanged to remove sugars, and protein 
sample was concentrated. Proteins were separated on SDS-PAGE (7 % gel) and proteins 
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The Coomassie stained polyacrylamide gel in Figure 6.1 (a.), showed a number of 
proteins that were bound to (lane 1) and eluted from lentil lectin Sepharose beads (lanes 
2 and 3). A protein at ~120 kDa was observed, indicated by the arrow [Fig. 6.1 (b), lane 
3]. This is in agreement with the expected molecular weight of soluble LDLr that was 
released into the medium of cultured cells. When the sample was reduced, the higher 
molecular weight bands dissociated into the 120 kDa band, as more of this component 
was seen, migrating just above 120 kDa marker [Fig. 6.1 (b.)]. Other bands were also 
observed which could be due to degradation products (~85 kDa band) or aggregation of 
soluble LDLr (high molecular weight bands in lane 3), or non-specific binding to other 
proteins. Detection using only the secondary antibody as a control showed no interaction 
Figure 6.1: Detection of soluble LDLr from plasma glycoproteins by 
SDS-PAGE (a) and Western blot (b). 
Plasma was incubated with lentil lectin Sepharose beads. After washing, the 
glycoproteins were eluted in 0.2 M α-D-mannopyranoside, and concentrated. 
Samples were separated by SDS PAGE (7 % gel) and stained with Coomassie or 
analysed with the rabbit polyclonal antibody to the LDLr. 
Lane 1:  lentil lectin Sepharose with bound glycoproteins, reduced with β-ME. 
Lane 2: 3 µl eluted glycoproteins, reduced with β-ME. Lane 3: 3 µl eluted 
glycoproteins, non-reduced. The arrow indicates a 120 kDa protein detected by the 
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with the bands of interest, indicating that the bands seen here were specific for the LDLr 




The experiment was repeated using the same conditions as before with different plasma 
samples. As a control, a medium sample containing recombinant soluble LDLr (Fig. 6.2, 
lane 1) was loaded onto the SDS-PAGE. A protein that migrated with the same Rf value 
(indicated by the arrow) as the recombinant soluble LDLr control was seen. The protein 
detected here in all the plasma glycoprotein samples (lanes 2-5) was the same size as the 
protein seen in Figure 6.1. This time there was a fainter signal compared to Figure 6.1, as 
a longer exposure was needed to detect this signal. The faint signal that was seen could 
have been due to less glyocoproteins in the eluted sample, and therefore less non-specific 
binding was also seen.  
  
Figure 6.2: Detection of soluble LDLr from plasma glycoproteins by 
western blot. 
Plasma was incubated with lentil lectin Ssepharose beads. After washing, the 
glycoproteins were eluted in 0.2 M α-D-mannopyranoside, and concentrated. Samples 
(3 µl) were loaded on 7% SDS PAGE and analysed with the rabbit polyclonal antibody 
to the LDLr. 
Lane 1: 20 µl Mmedium (harvested from CHO LDLr expressing cells). Lanes 2-5: A 
range of plasma glycoprotein samples. All the samples contained β-ME. The arrow 
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From Figures 6.1 and 6.2, it seemed likely that the protein which immuno-reacted with 
the LDLr antibody was soluble LDLr. However, the elution and further characterisation 
of the plasma glycoproteins proved problematic due to the tight interaction between the 
sugar moieties of proteins and the lentil lectin Sepharose beads resulting in elution of 
glycoproteins in the range of ~0.2 % -0.8 %. For this reason, this approach was not used 
in an attempt to purify soluble LDLr from plasma. 
 
6.2.2 Detection of soluble LDLr from plasma using IP 
IP was used to determine if soluble LDLr existed in plasma. Some plasma proteins have 
previously been isolated using antibody affinity chromatography (Sutcliffe et al., 1980; 
Cawston et al., 1986; Tseng et al., 2004). The ExactaCruz IP methodology was used to 
identify soluble LDLr. This approach enables one to immunoprecipitate with a mouse 
monoclonal antibody and to detect with a rabbit polyclonal antibody for the Western blot. 
Furthermore, the use of a HRP-linked secondary antibody that is specific for the rabbit 
polyclonal antibody avoids the detection of the light and heavy chains of the IP antibody. 
Pre-cleared plasma was used for the IP with the C7 monoclonal antibody, while the 
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From the Western blot (Fig. 6.3), the immunoprecipitated plasma sample showed two 
bands in the region of interest (in comparison to the soluble LDLr control), as well as a 
smaller component migrating at ~95 kDa. However, it is not certain if the ~140 kDa band 
is the only fragment released into plasma as a result of ectodomain shedding, as it is 
possible that the lower band is a differently shed form of soluble LDLr or a degradation 
product. Even though plasma was precleared using protein G, it did not completely 
remove all the IgG present in the sample. In addition, IgG and other high abundant 
proteins present in the plasma sample could have interfered with the IP, and therefore a 
more definitive signal was not seen. For IP, IgG and albumin removal is important to be 
able to obtain a more prominent signal. 
 
Figure 6.3: Detection of soluble LDLr from plasma by IP and western blot 
Precleared plasma was immunoprecipitated with a C7 monoclonal antibody to the 
LDLr and loaded on 7% SDS-PAGE and for western blot analysis it was probed with 
the rabbit polyclonal antibody to the LDLr.  
Lane 1: Imunnoprecipitate of plasma. Lane 2: Medium (harvested from CHO LDLr 
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6.2.3 Detection of soluble LDLr from enriched plasma 
The plasma proteome is a complex mixture of proteins and a major obstacle in finding 
small abundant proteins within the human plasma proteome is that the high abundant 
proteins mask those present in very low concentrations. This limitation is somewhat 
overcome with the emergence of albumin, IgG, albumin/IgG or other high abundance 
protein removal kits. However, these approaches are antibody based and use very small 
volumes, ranging from 50-100 µl.  
 
The Proteominer protein enrichment kit (Bio-Rad) uses the principle of a bead-based 
library of combinatorial peptide ligands to deplete high abundant proteins from plasma 
(Guerrier et al., 2006). When plasma is applied to the beads, the proteins bind to the 
ligands. When peptides become saturated by the high abundant proteins, excess proteins 
pass through the column. The complexity of the sample is reduced, while all 
representative proteins are maintained. After the plasma sample was applied, the beads 
were washed and the plasma proteins were eluted. After elution, plasma proteins were 
separated by SDS-PAGE. Following the enrichment of low abundance plasma proteins 
and separation by SDS-PAGE, a One-Step Western system was used, in which only 
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When the One-Step Western system was used, the non-reduced samples display a high 
molecular weight band at ~250 kDa band [Fig. 6.4 (a).] in addition to a band of ~120 
kDa. Both component intensities increased when an increasing concentration of proteins 
was loaded. The 250 kDa component could be a dimer of soluble LDLr that dissociates 
when reduced [Fig. 6.4 (b).] (van Driel et al., 1987). The amount of reduced sample was 
increased 10-fold to amplify the chances of seeing soluble LDLr, since the antibody used 
in this experiment was able to detect reduced LDLr albeit to a lesser extent. Under 
reduced conditions, the cysteine-rich receptor unfolds and the mobility of the protein is 
reduced (Daniel et al., 1983). In the reduced sample, two proteins were detected, one at 
~140 kDa that was likely the soluble LDLr migrating slower due to the reduction the 







































Figure 6.4: Detection of soluble LDLr from enriched plasma using a 
One-Step Western system. 
(a). Eluted, enriched plasma proteins, non-reduced (b). Eluted, enriched plasma 
proteins, reduced with β-ME. High abundance plasma proteins were removed from 
plasma by the enrichment of small abundant proteins by the Proteominer system 
(Bio-Rad), and separated on 7 % SDS-PAGE. The rabbit polyclonal antibody was 
used to detect soluble LDLr.  
 
 
  124 
component of ~85 kDa, which could be a degradation product. The reduced protein of 
~140 kDa corresponded to the size of soluble LDLr from medium, in addition to the 
bands seen in the plasma sample seen in Figure 6.3, lanes 2 and 1, respectively. The 
bands do not correspond exactly to the sizes seen in Figures 6.1 and 6.2, which could be 
due a different marker used in those Western blots.    
 
The presence of an LDLr dimer has been demonstrated before, where both the dimer and 
monomer were able to bind the LDLr antibody and radio-labelled LDL in ligand blots 
(van Driel et al., 1987). LDLr incubated with increasing concentrations of LDL followed 
by separation on native PAGE, showed a decrease in dimer and monomer bands under 
increasing LDL concentrations (Jeon and Shipley, 2000). A recombinant soluble LDLr 
fragment also formed a dimer (Marlovits et al., 1998c). 
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To achieve an improved signal for the reduced form of the receptor, a different LDLr 
antibody was used for the following experiment, as according to the suppliers, this 
antibody was able to bind both the reduced and non-reduced form of the LDLr. In the 
non-reduced medium sample, the soluble LDLr was detected as indicated by the arrow. 
The other non-specific bands were due to the antibody binding to proteins present in FCS 
in the sample as tested as a control before (data not shown). Perhaps some of the non-
specific bands were from the antibody binding to bovine soluble LDLr present in FCS. In 
the non-reduced plasma protein samples, the antibody detected a high molecular weight 
band [Fig. 6.5 (a).]. This band again disappeared on reduction with β-ME [Fig. 6.5 (b).]. 
In the reduced samples, a fainter band at ~100 kDa (indicated by the arrow), which was 
smaller than the recombinant soluble LDLr. There was also a prominent band at 85 kDa, 
Figure 6.5: Detection of soluble LDLr from enriched plasma using anti-goat 
LDLr 
(a). Medium (harvested from CHO LDLr expressing cells) was loaded as a control. Eluted, 
enriched plasma proteins, non-reduced (b). Cell lysate and medium (harvested from CHO 
LDLr expressing cells) were loaded as controls. Eluted, enriched plasma proteins, reduced 
with β-ME. High abundance plasma proteins were removed from plasma for the 
enrichment of small abundant proteins by the Proteominer system (Bio-Rad), and separated 
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as seen previously [Fig. 6.4 (b).]. The high molecular weight band could be an oligomer 
of the 85 kDa band. To eliminate the possibility of non-specific binding of the secondary 
antibody, the nitrocellulose membrane was stripped and reprobed with the secondary 
antibody alone. There were no bands detected by the secondary antibody, indicating that 
the interactions detected were solely due to the primary antibody used in Figure 6.5.  
 
6.2.4 Binding of soluble LDLr to its ligand 
Since the soluble LDLr shed from CHO LDLr expressing cells contained the ligand 
binding domain, it was determined whether soluble LDLr could bind its ligand LDL by 
using native and SDS-PAGE. Due to the reported molecular weight of LDL to be ~2500-
3500 kDa (Fisher et al., 1975), and the molecular weight of the soluble LDLr being ~140 
kDa (under non-reducing conditions) (Begg et al., 2004), gradient gel electrophoresis 
(GGE) was performed. This method is advantageous in that a high resolution is obtained 
during the separation of a range of high molecular weight and low molecular weight 
proteins within a particular sample. LDL was incubated with medium containing soluble 
LDLr and detected for LDLr by Western blotting. 
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Under native conditions, in the absence of LDL, soluble LDLr from conditioned medium 
was detected at ~140 kDa [Fig. 6.6 (a), lane 1]. When the LDL was added to soluble 
LDLr in conditioned medium a gel shift was observed with the band now running at a 
higher molecular weight [Fig. 6.6 (a), lane 2]. In the presence of the ionic detergent SDS, 
the soluble LDLr was detected at ~120 kDa, [comparing Fig. 6.6 (a) and (b)], the SDS 
present resulted in the protein becoming more negative, and migrating at a faster rate 
[Fig. 6.6 (b), lane 1]. When the same LDL-medium mixture was separated by GGE in the 
presence of SDS, the complex that was formed was disrupted before entering the gel and 
no gel shift was seen, since the LDLr was not bound to LDL. Hence, the soluble LDLr 















5-20 % Native PAGE 










5-20 % SDS-PAGE  
(a). (b). 
Figure 6.6: Interaction of soluble LDLr from medium and LDL from plasma, 
shown by GGE and western blot.  
Lane 1: 20 µg of medium proteins. Lane 2: 13.8 µg of medium proteins + 7.5 µg LDL. 
Medium and LDL were incubated on ice for 15 minutes, prior to loading. Samples were 
loaded on 5-20% gradient gels, under native (a), or denatured conditions (b). The rabbit 
polyclonal antibody was used to detect soluble LDLr.  
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6.3 Discussion 
Taking the lectin affinity chromatography, IP and protein enrichment experiments into 
account, it appears that the soluble LDLr does indeed exist in plasma, migrating as a 
~120 kDa protein, under non-reducing SDS-PAGE conditions with a similar Rf value as 
the shed LDLr seen in vitro. A factor causing variation between the levels of soluble 
LDLr for each of the above experiments could be the use of different methods and the 
use of different plasma samples. In addition to the 120 kDa band, smaller degradation 
products were also detected, indicating that proteases present in plasma cleaved the 
soluble LDLr further. This is probable, since the urinary LDLr corresponds to only part 
of the ligand binding domain (Molina et al., 2007). In all the Western blot experiments 
except for Figure 6.5, a rabbit polyclonal antibody was used, and a protein of soluble 
LDLr size as well as a smaller product was seen. However, in Figure 6.5 the ratio 
between the smaller band to the larger band was higher. A possible explanation could be 
that the LDLr which was cleaved further resulted in a confirmation that was suited for 
the goat polyclonal antibody, and therefore a stronger interaction occurred. Another 
factor in observing a lower amount of the 85 kDa component in Figure 6.4 (b) compared 
to Figure 6.5 (b), could be attributed to the fact that the eluted plasma proteins that were 
used in the latter experiment were stored for approximately two weeks at -20°C before 
being used. As a result, degradation in the protein sample could have occurred.  
 
Besides identifying the soluble form of the LDLr in plasma, the data also suggested that 
the soluble LDLr formed a dimer. The dimer formation of the full length membrane 
LDLr and purified LDLr was shown previously (van Driel et al., 1987). It was also 
suggested that dimer formation in intact cells occurred via the cytoplasmic tail, as 
mutants containing a stop codon at position 792 or 807, were unable to form dimers. 
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Furthermore a mutant containing a cysteine at 807 underwent increased dimerisation 
compared to wild-type, supporting the theory. On the other hand, it was suggested that 
the LDLr dimer formation occurred in the extracellular domain, in a confirmation 
favouring interactions between the EGF repeats (Jeon and Shipley, 2000). Moreover, a 
recombinant soluble LDLr has been shown to form a dimer, indicating that dimerisation 
can occur via the ligand binding domain (Marlovits et al., 1998c). It is plausible that 
dimerisation could occur through the ligand binding domain since this domain is 
cysteine-rich.  
 
From the ligand binding experiment, soluble LDLr from medium was able to bind LDL 
in the absence of SDS, since an LDL-LDLr complex was formed and a higher molecular 
weight was observed [Fig. 6.6 (a), lane 2]. In the presence of SDS this complex was 
disrupted before entering the gel and LDL did not associate with the LDLr [Fig. 6.6 (b), 
lane 2]. This was expected since the binding of the ligand to LDLr presumably takes 
place via the positively charged amino acids on the apo-B-100 protein of the LDL 
molecule, and the negative charged residues in the ligand binding domain of the LDLr 
(Brown et al., 1997; Innerarity, 2002). 
 
Binding of detergent solubilised full-length LDLr to LDL was studied in the same way, 
where the LDLr was incubated with LDL before analysis by native PAGE and Western 
blotting (Jeon and Shipley, 2000). In the presence of calcium, decreased levels of LDLr 
were shown with increased levels of LDL in the sample. However, the binding was not 
studied in the presence of SDS.  
 
  130 
A similar experiment was performed previously, where the interaction of LDLr and LDL 
was investigated and showed by ligand blotting after SDS-PAGE (Daniel et al., 1983). 
The difference between the experiment performed by Daniel et al., and the one presented 
in this study was that in their system the SDS was removed after transfer of proteins to 
nitrocellulose membranes, and the ligand was able to bind. In Figure 6.6 (b), lane 2, the 
SDS was not removed from the system, and the interaction between LDL and LDLr did 
not occur. Since the complex could not be formed, it did not enter the gel as a complex 
and was not seen as one [Fig. 6.6 (b), lane 2]. In the same publication however, they 
showed by a membrane filter assay that purified LDLr was able to bind LDL, as long as 
the receptor was not reduced, indicating that the intramolecular chains were intact, since 
LDLr denatured by guanidine was able to bind the ligand (Daniel et al., 1983). It may be 
possible though that through a dialysis step before ligand binding removed the guanidine 
present in the sample, and refolding of the protein occurred (Maxwell et al., 2003; Ma et 
al., 2008), resulting in binding of the ligand. It was also shown for a recombinant 
disulphide-rich soluble lectin-like oxidized LDL scavenger (LOX-1) receptor, that 
binding to oxidized LDL took place after a step-wise removal of guanidine (Vohra et al., 
2007).   
 
Possible roles for the ectodomain release of soluble LDLr family members have been 
proposed. Soluble LRP-1 was purified from plasma by ligand affinity and also shown to 
bind RAP ligand blots (Quinn et al., 1997; Quinn et al., 1999). The LRP-1 was suggested 
to modulate Aβ clearance from the brain, as well as in the systemic clearance of Aβ in 
the liver (Sagare et al., 2007; Deane et al., 2008). In addition the physiological role of 
soluble LRP-1 in plasma has been implicated to act as an Aβ “sink”, important in the 
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prevention of the amyloidogenic Aβ peptide in the brain, and prevention of Alzheimer’s 
disease.  
 
LRP-1, ApoER2 and vLDLr were shown to undergo release of the ICD following 
cleavage by a γ-secretase (May et al., 2002; May et al., 2003; Hoe and Rebeck, 2005). 
Ectodomain shedding of the LDLr family members such as ApoER2 and vLDLr 
increased in the presence of ligand (Hoe and Rebeck, 2005). The soluble forms of LDLr 
family members, vLDLr and ApoER2 were shown to bind some ligands, such as HRV-2 
and Reelin, respectively. The function of soluble ApoER2 was determined by showing 
that it binds to Reelin, acting as a dominant negative receptor and inhibited Reelin 
signaling in neurons. 
 
Soluble LDLr and vLDLr were suggested to be preventative in common cold infection 
by binding to HRV-2 in vitro (Marlovits et al., 1998a; Marlovits et al., 1998b). 
Recombinant LDLr comprising of the ligand binding domain was also shown to bind to 
β-VLDL. In addition a 28-kDa form of soluble LDLr in cultured cells was produced in 
response to IFN (Fischer et al., 1993). This fragment acts as an antiviral protein in cell 
culture. It may be possible that such a fragment exists in plasma or that this may be the 
same fragment that was purified from urine (Molina et al., 2007). A soluble form of the 
LDLr encompassing the ligand binding domain, proven to bind LDL, was shown to 
inhibit hepatitis C infection of hepatic cells, while the shorter urinary LDLr fragment 
could not bind LDL.  
 
Since the LDLr is as yet not known to be involved in signaling, and it is not confirmed 
whether the ectodomain release initiates the release of an ICD to function as a 
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downstream signal, the role of soluble LDLr in vivo is not clear. No other physiological 
function has yet been attributed to the function of soluble LDLr formation. It can only be 
speculated that since the soluble LDLr binds to LDL, it can prevent uptake of LDL into 
cells. However, we do not know what the half-life of soluble LDLr in plasma is for it to 
cause an effect. Cleavage of LDLr family members could affect protein turnover, 
reducing the half-life in cells and preventing  lipoprotein uptake (Rebeck et al., 2006). In 
addition to post-translational regulation by PCSK9, the LDLr appears to be targeted for 
down-regulation through ectodomain release, and subsequent binding of the released 
ectodomain to LDL and preventing uptake.   
 
In conclusion, the presence of a ~120 kDa soluble LDLr was shown to be present in 
plasma, which corresponded to the size of soluble LDLr formed in vitro, and probably 
undergoes further degradation. The soluble LDLr forms a dimer which dissociates when 
reduced. In addition, it was confirmed by native GGE that recombinant soluble LDLr 
bound to plasma LDL and in the presence of SDS the interaction was lost, which further 
confirmed that the charge of the receptor and ligand was important for binding.   
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Conclusions 
 
The aim of this thesis was to investigate the ectodomain cleavage of the LDLr, with 
respect to the role of TACE toward soluble LDLr formation in vitro and to establish if 
the existence of soluble LDLr is physiologically relevant.  
 
The production of soluble LDLr was previously shown to be a product of ectodomain 
shedding, and TACE was implicated in the ectodomain release of membrane-bound 
LDLr. Since there was no antibody available (during the initial stages of the project) that 
could detect soluble LDLr from medium by Western blot, the LDLr was tagged with 
GFP on the extracellular N-terminus in an attempt to study the localisation of the LDLr, 
allowing shed constructs to be assayed by fluorimetry to characterise the ectodomain 
shedding. However, stable transfection of GFP constructs was not successful. Also, the 
use of GFP as a tag for the LDLr to assess shedding levels was not feasible as the 
stability of the construct was compromised in mammalian cells. This was probably due to 
incorrect folding and subsequent degradation of the GFP. Therefore the use of the GFP to 
investigate the shedding of the LDLr could not be pursued any further. Moreover, an 
antibody that could detect soluble LDLr from medium was sourced during the course of 
this thesis and immuno-blotting with this antibody to the LDLr was used in assessing 
LDLr shedding levels.    
 
Neither GFP(s) nor the LDLr could be expressed in TACE+/+ mouse fibroblasts. The 
results from the GFP transfections indicated that there was a general problem of 
expressing constructs in these cells. In addition, cell lysates and medium of TACE+/+ 
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mouse fibroblasts that were transfected with the LDLr showed no presence of full-length 
LDLr or soluble LDLr, respectively.  
 
Knock-out cell lines were utilised to investigate whether TACE was involved in the 
shedding of the LDLr and thus its ectodomain release was assessed in TACE-/- mouse 
fibroblasts. Under constitutive conditions, TACE independent shedding of the LDLr 
occurred in TACE-/- mouse fibroblasts. This indicated that under constitutive conditions 
in the absence of TACE, other sheddase(s) take over the role of ectodomain cleavage, as 
was found with TNF-α and APP (Zheng et al., 2004; Deuss et al., 2008). Phorbol-
stimulated shedding of the LDLr in TACE-/- mouse fibroblasts did not increase over un-
stimulated conditions, indicating that TACE was a major sheddase of stimulated 
shedding, at least for the wt-LDLr and the 792-LDLr. The JD-LDLr mutant was possibly 
shed by a different secretase but this was not confirmed as levels could not be compared 
to levels in TACE+/+ mouse fibroblasts.  
 
In addition, shedding of the LDLr was assessed in CHO M2 cells, an alternative TACE 
deficient cell line, so that it could be compared to shedding in CHO A7 cells. By the 
evaluation and comparison of the ectodomain release of the LDLr in CHO M2 to that of 
CHO A7 cells, it was shown that the LDLr was a substrate almost completely dependent 
on cleavage by TACE both in the absence and presence of phorbol stimulation. The 
internalisation mutants did not undergo increased ectodomain release compared to wt-
LDLr in the absence or presence of phorbol in CHO M2 cells, which indicated that in the 
absence of TACE the lack of internalisation did not increase the ectodomain release of 
the LDLr.  
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Constitutive levels of soluble LDLr were 5-fold higher in the TACE-/- mouse fibroblasts 
than in the CHO M2 cells. From the fluorogenic TNF-α cleavage assays, the increased 
production of soluble LDLr could be attributed to the ~2.4-fold higher sheddase activity. 
Western blot analysis of ADAM 10 expression supported the results seen for the TNF-α 
cleavage assays, with a concomitant ~2.7-fold increase in ADAM 10 expression in the 
TACE-/- mouse fibroblasts compared to the CHO M2 cells. This suggested that ADAM 
10 was the major sheddase contributing to the elevated sheddase activity in TACE-/- 
mouse fibroblasts.   
 
Due to this finding, it was thought that ADAM 10 was a possible candidate sheddase 
involved in the constitutive shedding of the LDLr in TACE-/- mouse fibroblasts. Even 
though the co-immunoprecipitation experiments only revealed a self-association between 
the LDLr protein and not an association between LDLr and ADAM 10, this does not 
exclude the possibility of the involvement of ADAM 10 in the shedding of the LDLr.  
 
Results from the two TACE deficient cell lines indicated that in mouse fibroblasts: (i) 
soluble LDLr production was higher, (ii) TNF-α sheddase activity was higher and (iii) 
ADAM 10 expression was elevated. These data support previous findings which 
suggested that depending on the cell type and conditions investigated, different sheddases 
can be substituted in the absence of a particular sheddase, thus leading to the redundancy 
or compensatory mechanisms which exist between ADAMs (Chow and Fernandez-
Patron, 2007).   
 
In the absence of SDS a recombinant soluble LDLr bound plasma LDL, confirming that 
the ligand binding domain of the soluble LDLr was still able to bind ligand. However, in 
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the presence of SDS the interaction was lost, which highlighted the importance of the 
role of non-covalent interactions between the LDLr and ligand for binding.  
 
The detection of soluble LDLr in human plasma as determined by Western blot analysis 
suggests a physiological relevance for soluble LDLr formation in vivo. A smaller 
degradation fragment was also detected by these methods, which suggested that soluble 
LDLr released into plasma was cleaved by proteases at other sites within the ectodomain. 
The generation of a smaller LDLr fragment was also detected in human urine previously 
(Molina et al., 2007).  
  
The putative physiological function of soluble LDLr formation in human plasma could 
be the down-regulation of cell surface receptor, ectodomain release and concomitant 
binding to plasma LDL (or other ligands such as HRV-2), thus reducing LDL (or HRV-
2) uptake into cells (Marlovits et al., 1998a; Marlovits et al., 1998c). In addition, it was 
suggested previously that soluble LDLr could function as an LDL trap, if the LDLr were 
to become deposited in atherosclerotic plaques, potentially accelerating the harmful 
effects of atherosclerosis (Begg et al., 2004). Further studies on the in vivo production of 
soluble LDLr with respect to binding of ligands could elucidate the role of the LDLr in 
the prevention of the common cold, VSV, and hepatitis C infection. 
 
Further studies through the investigation of ADAM 10 inhibition/down-regulation in 
TACE-/- mouse fibroblasts could clarify the role of ADAM 10 in LDLr shedding. 
Additionally, since the JD-LDLr shedding was up-regulated by phorbol in the absence of 
TACE, ADAM 10 could possibly play a bigger role in the shedding of this construct. The 
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purification of soluble LDLr from plasma could be addressed as well, which needs extra 
optimisation methods, important for the determination of the cleavage site. 
 
PCSK9-mediated degradation and ectodomain release are two mechanisms of post-
translational regulation that the LDLr undergoes. Therefore future questions related to 
LDLr regulation to answer are, whether the increase of LDLr expression by statins 
impact LDLr shedding physiologically and what the implications are of TACE-mediated 
ectodomain release of the LDLr for cholesterol metabolism.  
 
This thesis has provided a characterisation of the ectodomain release of the LDLr and the 
implications of a soluble LDLr in plasma provide the foundation for the further 
investigation of soluble LDLr formation in vivo to understand its role in cholesterol 
metabolism.  
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Appendix I 
Primer sequences for the GFP constructs are shown in Fig. I. 
5’~TGCTCTAGAATGGGGCCCTGGGGC~3’ 




                Hind III 
5’~CCCAAGCTTTGCGGCCGCATCGATGGTACCGGATCCCACCCACTCGTGCA~3’ 
                Hind Not I            Cla I        Kpn I  Bam HI       
5’~CGGGGTACCGCAGTGGGCGACAGATGTGAAAGAAAG~3’ 
5’~CCCAAGCTTTCACGCCACGTCATCCTC~3’ 
              
                Hind III 
Forward primer signal peptide: 
Reverse primer signal peptide: 
Forward primer GFP: 
Reverse primer GFP(s): 
Reverse primer GFP(MCS): 
Forward primer LDLr: 
Reverse primer LDLr: 
Figure I: Primers used in the construction of GFP vectors and GFP-
LDLr fusion protein.  
The underlined sequence indicates incorporated restriction enzyme site sequences.  
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Primer sequences for mutagenesis are shown in Fig. II.
5’~CCTTCTATGGAAGAACTGACGTCTTAAGAACATCAACAGC~3’ 




Forward primer 792-LDLr: 
Reverse primer 792-LDLr: 
Forward primer JD-LDLr: 
Reverse primer JD-LDLr: 
                    Bfi I 
                    Aat II 
                    Bfi I 
Figure II: Primers used in the site-directed mutagenesis of the 
LDLr. 
Complementary mutagenic primers were designed containing the mutation of 
interest (shown in red), as well as a silent mutation (shown in bold) 
introducing a unique restriction enzyme site to facilitate screening. WatCut 
was used in the design of mutagenic primers 
(http://watcut.uwaterloo.ca/watcut/watcut/template.php Michael Palmer, 
University of Waterloo, Canada). Underlined sequences indicate novel 
restriction enzyme site sequences. 
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Appendix II 
 
Reagents and Buffers 
Ampicillin (100 mg/ml) 
100 mg Ampicillin in 1 ml water  
 
10 % AMPS 
0.1 g AMPS in 1 ml water 
 
40 % acrylamide stock 
40 % acrylamide  
1.06 % bis-acrylamide 
 
6 X DNA loading dye (5 ml) 
0.025 g Bromophenol Blue 
0.025 g Xylene Cyanol 
6 ml 50 % glycerol 
4 ml water  
 
Luria Agar (400 ml) 
4 g Tryptone                
2 g Yeast extract          
4 g NaCl                      
5 g Agar  
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Luria Broth (400 ml) 
4 g Tryptone                
2 g Yeast extract          
4 g NaCl  
                     
PBS 
8 g NaCl 
1.15 g Na2HPO4   
0.23 g KH2PO4 
0.23g KCl 
Water to litre pH 7.2-7.4 
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